Patent Grant
11172890
Pulse oximetry screening can identify some critical congenital heart defects (“CCHDs”), which also are known collectively in some instances as critical congenital heart disease. CCHDs are structural heart defects that often are associated with hypoxia among infants during the newborn period. Infants with CCHDs are at risk for significant morbidity or mortality. There are several defects that could be considered CCHDs. However, in the context of newborn pulse oximetry screening at the time of preparation of the present application, the Centers for Disease Control and Prevention (“CDC”) for the U.S. government classify seven (7) defects as CCHD: hypoplastic left heart syndrome, pulmonary atresia (with intact septum), tetralogy of Fallot, total anomalous pulmonary venous return, transposition of the great arteries, tricuspid atresia, and truncus arteriosus. According to the CDC, these seven CCHDs represent about seventeen to about thirty one percent (17-31%) of all congenital heart disease.
Patent ductus arteriosus (“PDA”) is common in infants with several or more of the above seven (7) defects. In the developing fetus, the ductus arteriosus (“DA”) 102 shown in
When the newborn takes its first breath, the lungs open and pulmonary vascular resistance decreases. In normal newborns, the DA is substantially closed within twelve to twenty four (12-24) hours after birth, and is completely sealed after three (3) weeks.
In the case of PDA, high pressure oxygenated blood from the aorta 104 leaks or flows back into the pulmonary artery 112 and back to the lungs 108 with normal deoxygenated venous blood. The additional fluid returning to the lungs increases lung pressure to the point that the infant may have greater difficulty inflating the lungs. This uses more calories than normal and often interferes with feeding in infancy. Moreover, an open (patent) DA 102 alters the flow in the descending aorta 118, which, as a result, changes the blood oxygen saturation in the feet.
Without screening, some newborns with CCHDs might be missed because the signs of CCHD might not be evident before an infant is discharged from the hospital after birth. Other heart defects might be considered secondary screening targets. Some of these heart defects can be just as severe as the primary screening targets and also require intervention soon after birth. These secondary targets include aortic arch atresia or hypoplasia, interrupted aortic arch, coarctation of the aorta, double-outlet right ventricle, Ebstein anomaly, pulmonary stenosis, atrioventricular septal defect, ventricular septal defect, and single ventricle defects (other than hypoplastic left heart syndrome and tricuspid atresia).
Current CDC recommendations focus on screening infants in the well-baby nursery and in intermediate care nurseries or other units in which discharge from the hospital is common during an infant's first week of life. At the time of preparation of the present application, the CDC promulgated a CCHD screening process 200 reproduced as
According to the CDC s CCHD screening process 200 of
The CDC recommends any infant receiving a positive screen receive a diagnostic echocardiogram, which would involve an echocardiogram within the hospital or birthing center, transport to another institution for the procedure, or use of telemedicine for remote evaluation. This can be expensive, disruptive, and possibly harmful to the infant. For example, at the time of preparation of the present application, an echocardiogram to verify an out-of-range (positive) screen could cost several hundred dollars.
Thus, false positives are to be avoided. The CDC believes that false positives are decreased if the infant is alert, and timing pulse oximetry screening around the time of newborn hearing screening improves efficiency.
Pulse oximetry screening may not detect all CCHDs, so it is possible for a baby with a negative screening result to still have a CCHD or other congenital heart defect.
In certain embodiments, a system for noninvasively measuring a physiological parameter of a patient to facilitate a diagnosis can include an electronic device having a display, a wireless transceiver, a memory device having processor-executable instruction stored thereon, and a hardware processor in communication with the display, wireless transceiver, and the memory. The hardware processor can be programmed to execute the processor-executable instructions stored in the memory so as to display, on the display, a request for at least one patient ID associated with a patient; receive an input including the at least one patient ID; validate the at least on patient ID using one or more validations rules; provide, on the display, instructions for obtaining a critical congenital heart defect (CCHD) screening of the patient; determine CCHD screening information; and transmit the CCHD screening information in association with the at least one patient ID to a gateway computing device.
The system of the preceding paragraph can be implemented together with any combination of the following features, among others: the hardware processor is programmed to execute the processor-executable instructions stored in the memory so as to further display, on the display, instructions to obtain a first measurement by positioning a first noninvasive sensor at a first measurement site on a patient; the hardware processor is programmed to execute the processor-executable instructions stored in the memory so as to further receive, from the noninvasive sensor, first signals responsive to a first physiological characteristic of the patient; the hardware processor is programmed to execute the processor-executable instructions stored in the memory so as to further calculate a first measured physiological parameter responsive to the first signals; the hardware processor is programmed to execute the processor-executable instructions stored in the memory so as to further display, on the display, instructions to obtain a second measurement by positioning a second noninvasive sensor at a second measurement site on the patient; the hardware processor is programmed to execute the processor-executable instructions stored in the memory so as to further receive, from the second noninvasive sensor, second signals responsive to a second physiological characteristic of the patient; the hardware processor is programmed to execute the processor-executable instructions stored in the memory so as to further calculate a second measured physiological parameter of the patient responsive to the second signals; the hardware processor is programmed to execute the processor-executable instructions stored in the memory so as to further display, on the display, the first and second measured physiological parameters; wherein the validation rules are configurable; wherein the hardware processor is programmed to execute the processor-executable instructions stored in the memory so as to further in response to determining that the at least one patient ID is not valid based on the validation rules, provide a notification to a user; wherein the hardware processor is programmed to execute the processor-executable instructions stored in the memory so as to further allow the user to bypass the notification; wherein the gateway computing device is configured to transmit the CCHD screening information in association with the at least one patient ID to a data aggregator/translator computing device; wherein the gateway computing device is further configured provide communications among a plurality of patient devices and the data aggregator/translator computing device; wherein the hardware processor is programmed to execute the processor-executable instructions stored in the memory so as to further in response to receiving, from the gateway computing device, a message indicating a need to re-screen a patient for CCHD, display a notification; wherein message is received via the data aggregator/translator computing device, and wherein at least one of the gateway computing device or the data aggregator/translator computing device determines the message is to be provided to the system; wherein the data aggregator/translator computing device is configured to deduplicate patient data received from the gateway computing device; wherein the data aggregator/translator computing device is configured to transmit the CCHD screening information in association with the at least one patient ID to an electronic medical record (EMR) system; wherein the data aggregator/translator computing device is further configured to aggregate patient data from a plurality of gateway computing devices.
In certain embodiments, a system for noninvasively measuring a physiological parameter of a patient to facilitate a diagnosis can include an electronic device having a display, a wireless transceiver, a memory device having processor-executable instruction stored thereon, and a hardware processor in communication with the display, wireless transceiver, and the memory. The hardware processor can be programmed to execute the processor-executable instructions stored in the memory so as to display, on the display, instructions to obtain a first measurement by positioning a first noninvasive sensor at a first measurement site on a patient; receive, from the noninvasive sensor, first signals responsive to a first physiological characteristic of the patient; calculate a first measured physiological parameter responsive to the first signals; display, on the display, instructions to obtain a second measurement by positioning a second noninvasive sensor at a second measurement site on the patient; receive, from the second noninvasive sensor, second signals responsive to a second physiological characteristic of the patient; calculate a second measured physiological parameter of the patient responsive to the second signals; display, on the display, the first and second measured physiological parameters; transmit, with the wireless transceiver, the first and second measured parameters over a network to a clinician; and initiate, with the wireless transceiver, a telemedicine session with the clinician over the network to obtain a diagnosis based on the first and second measured parameters.
The system of the preceding paragraph can be implemented together with any combination of the following features, among others: the first measured parameter can be oxygen saturation and the second measured parameter can be blood pressure; the wireless transceiver can be configured to receive an instruction to re-run one or both of the first and second measurements; the hardware processor can be further configured to output a selection of clinicians, receive a selection of one of the clinicians from the patient, and initiate a communication session with the clinician; wherein the telemedicine session comprises a video of the clinician; wherein the hardware processor can be further configured to receive an indication of a prescription; wherein the hardware processor can be further configured to instruct the patient to take a temperature reading; wherein the hardware processor can be further configured to instruct the patient to perform the first measurement again due to low signal confidence in the first measurement.
In other embodiments, a system for noninvasively measuring a physiological parameter of a patient to facilitate a diagnosis can include an electronic device in communication with a noninvasive sensor coupled with a patient. The electronic device can be configured to drive light sources of the noninvasive sensor and to receive output signals from the noninvasive sensor. The electronic device can include a hardware processor that can process the output signals from the noninvasive sensor to measure a physiological parameter associated with the patient; determine, based on a level of the physiological parameter, that critical congenital heart defect (CCHD) screening is recommended; transmit a notification that the CCHD screening is recommended; and subsequent to said transmission of the notification, and in response to receipt of an indication that CCHD screening is to be performed: display, on a display of the electronic device, instructions to position the noninvasive sensor at a first measurement site on the patient; obtain, with the noninvasive sensor, first physiological data from the first measurement site; display, on the display of the electronic device, instructions to position the noninvasive sensor at a second measurement site on the patient; obtain, with the noninvasive sensor, second physiological data from the second measurement site; process the first physiological data and said second physiological data; and output a difference between said first physiological data and the second physiological data, the difference used to determine the existence of a CCHD.
The system of the preceding paragraph can be implemented together with any combination of the following features, among others: the hardware processor can be further configured to determine, based on the level of the physiological parameter, that critical congenital heart defect (CCHD) screening is recommended by determining that oxygen saturation is below a threshold level; the first physiological data can include a first window of physiological data, the second physiological data can include a second window of physiological data, and the first window and the second window can be non-overlapping in time. Further, the hardware processor can be further configured to process said first physiological data and said second physiological data by: calculating a plurality of first physiological parameter values corresponding to the first window; calculating a plurality of second physiological parameter values corresponding to the second window; determining first confidence values corresponding to the first physiological parameter values; determining second confidence values corresponding to the second physiological parameter values; selecting a first selected physiological parameter value from the first physiological parameter values, the first selected physiological parameter value having a highest value of the first confidence values; selecting a second selected physiological parameter value from the second physiological parameter values, the second selected physiological parameter value having a highest value of the second confidence values; and calculating the difference between the first selected physiological parameter value and the second selected physiological parameter value.
Moreover, the systems of the preceding paragraphs can be implemented together with any combination of the following features, among others: the hardware processor can be further configured to output an indication that the first and second selected physiological parameter values were selected to calculate the difference; the hardware processor can be further configured to output an indication that the first and second selected physiological parameter values were selected to calculate the difference due to the first and second selected physiological parameter values having the highest values of the first and second confidence values; the hardware processor can be further configured to display, on the display, a configuration option that enables a clinician to specify a recommended period of time between CCHD screenings; the hardware processor can be further configured to perform one or both of the following: display an indication recommending the CCHD screening, or transmit, over a network, an indication recommending the CCHD screening; the hardware processor can be further configured to display the first and second physiological parameter values, together with a third physiological parameter value, used in determining to recommend the CCHD screening; the hardware processor can be further configured to display, on the display, whether results of the CCHD screening were sent to an electronic medical record; and the hardware processor can be further configured to display, on the display, an option to send the results of the CCHD screening to the electronic medical record.
Additional embodiments of the disclosure are described below in reference to the appended claims, which may serve as an additional summary of the disclosure.
In various embodiments, systems and/or computer systems are disclosed that comprise a computer readable storage medium having program instructions embodied therewith, and one or more processors configured to execute the program instructions to cause the systems and/or computer systems to perform operations comprising one or more aspects of the above- and/or below-described embodiments (including one or more aspects of the appended claims).
In various embodiments, computer-implemented methods are disclosed in which, by one or more processors executing program instructions, one or more aspects of the above- and/or below-described embodiments (including one or more aspects of the appended claims) are implemented and/or performed.
In various embodiments, computer program products comprising a computer readable storage medium are disclosed, wherein the computer readable storage medium has program instructions embodied therewith, the program instructions executable by one or more processors to cause the one or more processors to perform operations comprising one or more aspects of the above- and/or below-described embodiments (including one or more aspects of the appended claims).
For purposes of summarizing the disclosure, certain aspects, advantages and novel features thereof have been described herein. Of course, it is to be understood that not necessarily all such aspects, advantages or features will be embodied in any particular embodiment of the invention.
The following drawings and the associated descriptions are provided to illustrate embodiments of the present disclosure and do not limit the scope of the claims.
In one embodiment, automated critical congenital heart defect (“CCHD”) screening systems and processes are described. A caregiver may be guided to use a single or dual sensor pulse oximeter to obtain pre- and post-ductal blood oxygenation measurements. A delta of the measurements indicates the possible existence or nonexistence of a CCHD. Errors in the measurements are reduced by a configurable measurement confidence threshold based on, for example, a perfusion index. Measurement data may be stored and retrieved from a remote data processing center for repeated screenings.
The CCHD screening process of
Rather, in most if not all circumstances, the CCHD screening process of
Drawbacks may occur using the single sensor implementation. For example, there will be a time differential between the first baseline measurement and the second alternate site measurement when the caregiver changes sites. In infants, the parameters measureable with today's oximeters, including but not limited to oxygen saturation (“SpO2”), vary within relatively short periods. This is exacerbated when infants are exited, crying, or otherwise agitated.
In the most straightforward scenario where the SpO2 measurements are somewhat varying, the single sensor implementation of CCHD screening may determine, for example, an infant's SpO2 during a valley or trough of varying SpO2 values for the baseline measurement, and quite accidentally during a peak of varying SpO2 values for the alternate measurement. Such time displaced measurements could appear anywhere on an infant's SpO2 waveform. Thus, the differential between the baseline measurement and the alternate measurement, which is the key to determining positive or negative screenings under the CCHD screening process, could be subject to error. This is exacerbated as the CCHD screening process may require three (3) or more screenings before rendering a conclusion. Thus, a screening process may include measurements taken under different data conditions at each screen, and then again across the screens.
To overcome these and other drawbacks, the present disclosure includes systems and methods automating CCHD screening and detection. In an embodiment, a processor executes one or more processing modules to improve a likelihood that during a single sensor implementation of CCHD screening, the measurement values while time displaced, correspond to data conditions similar to one another. In addition, the processing module may determine the best sites for measurements.
In an embodiment, an oximeter or communicating monitor controls and tracks the implementation of the screening process, including instructions to caregivers on next steps. For example, a straightforward instruction may include “Attach Sensor to Right Hand,” “Attach Sensor to Alternate Site,” “Attach Sensor to Right Foot,” “Attach Sensor to Left Foot,” “Calm Patient,” “Adjust Sensor Positioning,” or the like. The oximeter may also include a quality indicator providing information on the confidence in the screening measurements. A quality measure may be included for each measurement, for the entire screen, or the like. For example, the display may indicate “Positive Screen, 72% Confidence.” In an embodiment, a minimum confidence threshold may be used to instruct a caregiver to repeat the measurements and/or restart the screening process. Moreover, the oximeter may produce an audio/visual alarm indicating time for a repeat screen, may accept patient information including a patient identifier, and the like.
In other embodiments, the oximeter may communicate with a host digital network or system to store or upload measurement data associated with a unique identifier to a remote processing center. That network or system may include multiple networks or systems. However, the oximeter may access previously stored information, such as, for example, earlier screening data stored at the remote network, to complete or increment the CCHD screening process. In an embodiment, a first network may be an institutional network such as a hospital data system, a cellular or other data system, or the like, wirelessly communicating with the oximeter or monitor. The system or systems eventually allow communication to a remote data server or processing center that stores the measurement information in a manner that provides for retrieval and appropriate association with newly acquired data.
Embodiments of the present disclosure generally relates to systems and methods automating critical congenital heart defects (“CCHDs”) screening and detection. In an embodiment, the CCHD screening process may be implemented on a single site pulse oximeter. A caregiver will apply the pulse oximeter sensor to the first site, such as the right hand, and take baseline measurements including, for example, blood oxygen saturation (“SpO2”). The caregiver will then remove the pulse oximeter sensor from the first site, and transfer it to the second site, such as, for example, a foot or left hand, and take measurements. As shown in
As used herein, the terms pulse oximeter, CCHD screening system, CCHD measurement device, and CCHD monitor may be used interchangeably.
In a single sensor implementation of noninvasive PDA determination or CCHD screen (as described below in referenced to
A sensor may then be placed on a foot to provide oxygen status for blood supplied from the descending aorta 118. The shunt at the ductus arteriosus 102 affects aortic flow. In particular, the shunt allows a transitory left-to-right flow during systole from the high pressure aorta 104 to the low pressure pulmonary artery 106 circulation. This left-to-right flow through the shunt at the ductus arteriosus 102 alters the flow in the descending aorta 118 and, as a result, affects the oxygen saturation value and plethysmograph waveform measured at the foot. The PDA condition, therefore, may be manifested as a normal plethysmograph with a characteristically narrow peak and well-defined dicrotic notch at the right-hand baseline site compared with a damped plethysmograph with a broadened peak and reduced or missing notch at the foot site. Further, the foot site waveform may be phase shifted from the baseline waveform. These plethysmograph differences are accompanied by comparable differences in arterial oxygen saturation values between the right-hand site and the foot site.
As an alternative, the sensor may be placed on the left hand to provide oxygen status for blood circulating from the left ventricle through the left subclavian artery 120 that supplies the left arm. Because the left subclavian artery 120 is nearer the shunt at the ductus arteriosus 102 than the further upstream innominate artery 116, it may experience some alteration in flow due to the shunt at the ductus arteriosus 102. The PDA condition, therefore, may also be manifested as an altered plethysmograph waveform at a left hand site as compared with the right hand baseline site, although likely to a lesser degree than with a foot site. Thus, the PDA condition, and thus a CCHD condition, can be detected and its treatment monitored from a delta in saturation (i.e., difference in SpO2) values and plethysmograph morphology and phase comparisons between a right hand baseline sensor site and one or more other sites, such as the left hand or foot. One of ordinary skill will recognize that multiple site comparisons using an oximeter may also be used to detect other cardiac abnormalities that cause mixing of oxygenated and deoxygenated blood, such as a ventricular hole or a patent foramen. Further, abnormal mixing of oxygenated and deoxygenated blood may also be manifested in physiological data measurements other than oxygen saturation provided by an advanced patient monitor or pulse oximeter.
The sensor 304 may include photocommunicative components, such as an emitter, a detector, and other components. The emitter may include a plurality of sets of optical sources that, in an embodiment, are arranged together as a point source. The various optical sources may emit a sequence of optical radiation pulses at different wavelengths towards a measurement site, such as a patient's finger. Detectors may then detect optical radiation from the measurement site. The optical sources and optical radiation detectors may operate at any appropriate wavelength, including infrared, near infrared, visible light, and ultraviolet. In addition, the optical sources and optical radiation detectors may operate at any appropriate wavelength, and such modifications to the embodiments desirable to operate at any such wavelength will be apparent to those skilled in the art. In some embodiments, the sensor 304 may be any of a disposable, reusable, and/or resposable sensor. Generally, for CCHD measurements, a sensor configured for use with an infant is desirable. In some embodiments, this may include a finger, toe, or ear sensor. In an embodiment, the sensor 304 may also be a wrist-type sensor configured to surround the wrist or ankle of an infant.
The sensor 304 is coupled to the pulse oximeter 300 that processes and/or displays the sensor 304's output, on, for example, display 302. The sensor 304 may additionally be coupled to one or more monitors that process and/or display the sensor 304's output. As described below in reference to
The sensor 304 may be integrated with a monitor (such as the pulse oximeter 300), for example, into a handheld unit including the sensor 304, a display and user controls. In other embodiments, the sensor 304 may communicate with one or more processing devices. The communication may be through wire(s), cable(s), flex circuit(s), wireless technologies, or other suitable analog or digital communication methodologies and devices to perform those methodologies. Many of the foregoing arrangements allow the sensor 304 to be attached to the measurement site while the device (such as the pulse oximeter 300) is attached elsewhere on a patient, such as the patient's arm, or placed at a location near the patient, such as a bed, shelf or table. The sensor 304 and/or pulse oximeter 300 may also provide outputs to a storage device or network interface.
The signal processor 326 may provide various signals through the front-end interface 324 and the communications link 322 that control the operation of the sensor 304. For example, the signal processor 326 may provide an emitter control signal to the sensor 304. Additionally, measurement data may be transmitted from the sensor 304 to the signal processor 326. As also shown, the optional memory 328 may be included in the front-end interface 324 and/or in the signal processor 326. This optional memory 328 may serve as a buffer or storage location for the front-end interface 324 and/or the signal processor 326, among other uses.
The user interface processor 330 may provide an output, for example, on the display 302, for presentation to a user of the pulse oximeter 300. The user interface processor 330 and/or the display 302 may be implemented as a touch-screen display, an LCD display, an organic LED display, or the like. In addition, the user interface processor 330 and/or display 302 may include a flip screen, a screen that can be moved from one side to another on the pulse oximeter 300, or may include an ability to reorient its display indicia responsive to user input or device orientation. In alternative embodiments, the pulse oximeter 300 may be provided without the display 302 and may simply provide an output signal to a separate display or system.
The storage 334 and the network interface 336 represent other optional output connections that can be included in the pulse oximeter 300. The storage 334 may include any computer-readable medium, such as a memory device, hard disk storage, EEPROM, flash drive, or the like. Various software and/or firmware applications can be stored in the storage 334, which may be executed by the signal processor 326 and/or another processor of the pulse oximeter 300. The network interface 336 may be a serial bus port (RS-232/RS-485), a Universal Serial Bus (USB) port, an Ethernet port, a wireless interface (e.g., WiFi such as any 802.1x interface, including an internal wireless card), or other suitable communication device(s) that allows the pulse oximeter 300 to communicate and share data with other devices (such as, for example, a remote data processing center as described below in reference to
Although not shown in the depicted embodiment, the pulse oximeter 300 may include various other components or may be configured in different ways. For example, the sensor 304 may measure additional advanced parameters. As described below, the pulse oximeter 300 may prompt the user to take specific actions through the display 302 to, for example, accomplish the CCHD screening process.
At box 366, the gathered pre- and post-ductal measurement data is processed by, for example, the signal processor 326. The gathered data is processed to provide both screening results (for example, the pre- and post-ductal SpO2 measurements and the delta between the two), but also to reduce errors in the measurements. As stated above, drawbacks arise when data from each time-displaced measurement (baseline and alternate, pre- and post-ductal) is not carefully selected. For example, normal infant SpO2 values may drift up and down more than two percent (2%). If a baby holds its breath during onset of crying, values may drift more than twenty percent (20%) in a very short time. If by chance the baseline was taken at a coincidental peak in normal variation, and the alternate was taken during crying or even at a valley or trough of normal variation, such error may impact a CCHD screening process, which, as shown in
As described above,
Referring back to
Referring back to box 366 in
In an embodiment, indications of motion may advantageously cause an audio/visual message to be presented to a caregiver to calm the patient before measurements can be used. In an embodiment, a minimum wait time may ensure that actual stabilization of the data occurs, such as for example, about ten (10) to twenty (20) seconds or more may need to pass after an indication of cessation of motion in the patient.
In an embodiment, the features of the plethsmographic data or of the oxygen saturation data values can be analyzed to determine when to use measurement data. In the case of the plethsmographic data, determination of how well the waveform fits a model may guide confidence measurements or indicate signal noise. With saturation data, troughs and peaks, and their respective severities may be determined so that measurements for each site are chosen during similar or the same waveform feature, such as, for example, using measurements that correspond to peaks for each site. In an embodiment, the natural high and low cycles of oxygen saturation are used to correlate the measurements. For example, typical pre- and post-ductal SpO2 measurements are illustrated in
In another embodiment, instead of correlating pre- and post-ductal measurements using natural cycles, the system can select a measurement from each window of data that has the highest signal confidence and compare those two measurements. The system can display which pre- and post-ductal measurements were selected from the window of data. For example, the system can display a graph or trend of pre-ductal measurements and a graph or trend of post-ductal measurements, along with some indicator on each graph or trend (such as a dot, X, square, or the like) showing which value was selected. By showing the clinician this graph or trend information, the system can provide the clinician with more data with which to make an informed diagnosis of CCHD. With this additional information about measurements in the windows, which measurements were selected, and confidence of the measurements (which may be shown for some or all measurements in the window), a clinician may be more informed and even decide to change the diagnosis recommended by the system.
Referring back to box 366 in
In an embodiment, phases in the respiration cycle may be accounted for to select measurement data. For example, measurement values may correspond to only data during, for example, the inspiration phase, or the like. In an embodiment, respiration or pulse rates may qualify or disqualify measurement data, based on, for example, rate stability or the like.
Other parameter information may also be used. For example, perfusion index (“PI”) information may provide indicators on when to select measurement data. In an embodiment, PI may vary for reasons unrelated to CCHD and therefore can be used in certain implementations, such as ranges that qualify or disqualify measurement data or the like. For example, the perfusion index may indicate that signal quality is sufficiently high to use measurement data. A PI measurement is also illustrated in
In box 368 of
In box 370, the results of the CCHD screening are reported to the caregiver/patient/user. This may be accomplished, for example, by displaying the results on the display 302 as a number, color, and/or other symbol, and/or aurally in the form of, for example, an alarm.
An artisan will recognize from the disclosure herein a wide variety of indicators or combinations of indicators for determining when to select measurement data for use in CCHD screening processes. For example, segments or whole windows of data for the various parameters and indicators discussed in the foregoing may be combined to provide additional insight into measurement selection. Moreover, any or combinations of the foregoing may be used to adjust a particular measurement instead of seeking a different measurement.
In this stereo embodiment of two (2) or more sensors, while there may not necessarily be time differentials between measurements, the data from each sensor may be of varying quality. Thus, many of the same procedures disclosed in the foregoing will apply. For example, at a particular time, the data from the baseline sensor may be clean with a high confidence while the data from the alternate sensor may have low quality from motion artifact, such as, for example, an infant kicking but not moving their right hand. Thus, the signal processing device 406 may use the foregoing processes to select measurement values from each sensor at different times. In such cases, determining which measurements should be used involves determinations similar to those used in the single sensor implementation. Alternatively, the signal processing device 406 may wait and select a time when both sensors produce usable measurement data, similar data conditions, or the like.
In an embodiment, the signal processing device 406 determines measurements for each of first sensor 408 and second sensor 409, and forwards measurement values to the pulse oximeter 400. The monitor 400 advantageously includes CCHD screening modules that guide a caregiver through the screening process. In other embodiments, the signal processing device 406 executes the screening and sends flags or messages to the display 402 and/or the portable oximeter 404 directing the display 402 and/or the portable oximeter 404 to display caregiver instructions and/or output results.
Although disclosed as the processing device 406 separate from the pulse oximeter 400, an artisan will recognize from the disclosure herein that the processing of the signal processing device 406 may be incorporated into the pulse oximeter 400 and/or the portable oximeter 404.
In an embodiment, the remote data processing center 504 may store, for example, Patient ID's, device information (such as, for example, patient monitor 502 device information), sensor information, measurement data, screening data, and/or screening determinations for comparisons with later screening events. For example, the CCHD screening process of
In an embodiment, the pulse oximeter 300 may communicate with network 506 (or other host digital network or system) to store or upload measurement data associated with a unique identifier (e.g., a patient ID) to remote data processing center 504. The network 506 may include multiple networks or systems. The pulse oximeter 300 may access previously stored information, such as, for example, earlier screening data stored at the remote data processing center 504 of a remote network, to complete or increment the CCHD screening process. In an embodiment, a first network may be an institutional network such as a hospital data system, a cellular or other data system, or the like, wirelessly communicating with the pulse oximeter 300 or monitor. The system or systems eventually allow communication to a remote data processing center 504 or other processing center that stores the measurement information in a manner that provides for retrieval and appropriate association with newly acquired data.
As will be described in detail below,
Once all of the settings are configured, the CCHD screening device of the present disclosure provides step by step instructions for performing a CCHD test protocol.
Once the pre-ductal measurement is obtained, the instructions move on to the instruction screens of
The instructions continue with
Although the foregoing has been described in terms of certain preferred embodiments, other embodiments will be apparent to those of ordinary skill in the art from the disclosure herein. For example, other CCHD screening methodologies may take advantage of the processes for matching measurements disclosed herein. Moreover, data conditions from one screen may influence when measurements are chosen for subsequent screens. For example, if choosing according to peaks in the SpO2 values was implemented to match measurement conditions in one screen, the same may be used or implemented in subsequent screens. Accordingly, the present disclosure is not intended to be limited by the reaction of the preferred embodiments, but is to be defined by reference to the appended claims.
In addition to the foregoing, all publications, patents, and patent applications mentioned in this specification are herein incorporated by reference to the same extent as if each individual publication, patent, or patent application was specifically and individually indicated to be incorporated by reference.
Moreover, the oximeters discussed in the foregoing may include many or all of the features of basic pulse oximeters that determine measurements for blood oxygen saturation (“SpO2”), pulse rate (“PR”) and plethysmographic information, to read-through-motion oximeters, to co-oximeters that determine measurements of many constituents of circulating blood. For example, Masimo Corporation of Irvine Calif. (“Masimo”) manufactures pulse oximetry systems including Masimo SET® low noise optical sensors and read through motion pulse oximetry monitors for measuring SpO2, PR, perfusion index (“PI”) and others. Masimo sensors include any of LNOP®, LNCS®, SofTouch™ and Blue™ adhesive or reusable sensors. Masimo oximetry monitors include any of Rad-8®, Rad-5®, Rad-5v® or SatShare® monitors.
Also, many innovations improving the measurement of blood constituents are described in at least U.S. Pat. Nos. 6,770,028; 6,658,276; 6,157,850; 6,002,952; 5,769,785 and 5,758,644, and are incorporated by reference herein. Corresponding low noise optical sensors are disclosed in at least U.S. Pat. Nos. 6,985,764; 6,813,511; 6,792,300; 6,256,523; 6,088,607; 5,782,757 and 5,638,818, and are incorporated by reference herein.
Masimo also manufactures more advanced co-oximeters including Masimo Rainbow® SET, which provides measurements in addition to SpO2, such as total hemoglobin (SpHb™), oxygen content (SpCO™), methemoglobin (SpMet®), carboxyhemoglobin (SpCO®) and PVI®. Advanced blood parameter sensors include Masimo Rainbow® adhesive, ReSposable™ and reusable sensors. Masimo's advanced blood parameter monitors include Masimo Radical-7™, Rad87™, and Rad-57™ monitors as well as Pronto and Pronto-7 spot check monitors.
Innovations relating to these more advanced blood parameter measurement systems are described in at least U.S. Pat. Nos. 7,647,083; 7,729,733; U.S. Pat. Pub. Nos. 2006/0211925; and 2006/0238358, incorporated by reference herein.
Such advanced pulse oximeters, low noise sensors and advanced blood parameter systems have gained rapid acceptance in a wide variety of medical applications, including surgical wards, intensive care and neonatal units, general wards, home care, physical training, and virtually all types of monitoring scenarios.
Thus, by employing the embodiments of the CCHD screening processes and systems disclosed herein, CCHD, particularly PDA, may be more accurately detected and diagnosed. Specifically, false positives may be reduced, variances in SpO2 may be detected and filtered, caregivers may be more properly directed, and/or measurement confidence may be evaluated, among other advantages.
CCHD screening, as well as other forms of patient monitoring, can be performed remotely using telemedicine technologies. In addition to having its ordinary meaning, the term “telemedicine,” as used herein, can refer to the remote diagnosis and/or treatment of patients using telecommunications technology. In one form, telemedicine can include a doctor communicating with a patient via video, with both the patient and the doctor able to see video and hear audio of the other, although one way video feeds (or two-way audio without video feeds) are used in some implementations. Telemedicine can facilitate more efficient and coordinated care, making homestay a possibility for a variety of patients. Remote monitoring and surveillance, along with virtual consultations, can reduce hospital admissions and length of stay, cutting costs while reinforcing continued routine care and self-management. However, limited integrated communication capabilities, lack of device interoperability, and poor network connectivity have hindered the rapid adoption of telemedicine solutions.
Embodiments of noninvasive point-of-care monitoring devices described herein are capable of gathering patient data from a variety of third-party devices connected via Bluetooth and transmitting patient data to remote locations and to electronic medical records (EMRs). Some point-of-care devices described herein can also offer built-in cameras, facilitating one- and two-way patient-clinician communication.
Some point-of-care devices described herein can have the ability to serve as a connectivity hub for multiple third-party and proprietary devices, aggregating the data from each peripheral device via Bluetooth. In addition, the point-of-care devices can facilitate the transmission of patient data to clinicians and live video conferencing, allowing a single device to serve as an all-inclusive, integrated solution. Embodiments of such a device, which may be used to implement any of the features described herein, are disclosed in U.S. Pub. No. 2015/0097701, filed Oct. 10, 2014, titled “System for Displaying Medical Monitoring Data,” the disclosure of which is hereby incorporated by reference in its entirety.
Any of the devices described herein can include a built-in camera, which can enable live, high-resolution (or lower resolution) video and audio feeds directly from the device to a central monitoring station (e.g., nurse's station) or to clinicians' devices (such as phones, tablets, laptops, computers, TVs, etc.), allowing clinicians to provide on-demand care and support. Real-time, two-way communication can allow care providers to manage individualized care plans, make efficient, informed assessments, and provide cost-effective, high-quality care at patients' convenience. One-way, surveillance monitoring can enable care providers to observe patient movements and listen to breathing for virtual assessment without disturbing the patient.
Although telemedicine may be used in hospital or other clinical settings, it can also be beneficial to use telemedicine in patients' homes (or wherever patients may be). A patient at home or mobile can use an electronic device, such as a phone, tablet, laptop, or desktop to communicate with a clinician. The patient may be provided monitoring equipment that interfaces with the patient's electronic device, such as noninvasive sensors (e.g., a blood pressure cuff). Outside of a hospital or clinical setting, however, patients may struggle to use patient monitoring equipment properly. Similarly, patients may struggle to interpret the measurements obtained from patient monitoring equipment. A patient may take a blood pressure measurement at home, for instance, but may be unaware whether the measurement is within normal range or whether it represents a potentially serious condition.
Certain embodiments of this disclosure describe a telemedicine system that can address some or all of the above concerns, among possibly others. The telemedicine system can advantageously guide patients through automated data collection and can facilitate live video chats with patient-selected health practitioners to discuss appropriate treatment and medications. The telemedicine system can act as a self-service point-of-care solution for patients outside of a traditional clinical setting. With the integrated capability to connect with their local clinician as needed, the telemedicine system can empower patients to proactively monitor their health status.
The telemedicine system can guide patients step-by-step to perform personal vital signs measurements. These measurements can be spot-check or continuous measurements, including, for example, one or more of oxygen saturation (SpO2), pulse rate, perfusion index, and respiration rate from a pulse oximetry sensor, as well as optionally temperature or blood pressure. Other physiological parameters can also be measured using these or other sensors, such as heart rate from an ECG sensor, respiration rate from an acoustic sensor, or a hemoglobin measurement (such as SpHb, total hemoglobin; SpMet, methemoglobin; or SpCO, carboxyhemoglobin, all available from Masimo Corporation of Irvine, Calif.) from an optical sensor. Any subset of these or other measurements may be taken. The telemedicine system can summarize the patient's measurements, optionally indicating which measurements are outside of normal range (such as abnormally high temperature). After reviewing results, the patient may be prompted to select a local or remote clinician to consult in a telemedicine session.
If the patient would like to consult with a clinician, the telemedicine system can provide a list of care providers in the vicinity (or remote) that are available for live audio and/or video conferencing. The selected care provider may receive a copy of the patient's vital signs spot-check results and may provide a real-time, virtual consultation with the patient using the integrated audio and/or video feed. At the conclusion of the virtual consultation, the patient's prescription can be sent directly to the desired pharmacy and a copy of the results may be sent to the patient (e.g., via email).
Features of the telemedicine system are described in detail below with respect to
The MNS 1710 can communicate with the home/mobile clinician devices 1718 over a network 1708 and the home mobile patient devices 1720 of a network 1708. The example networks 1708 shown can be local area networks (LAN), wide area networks (WAN), the Internet, an intranet, combinations of the same or the like. Any type of clinician computing device 1718 can communicate with the MNS 1710 including, for example, laptops, desktops, servers, work stations, tablets, wireless handheld devices such as cell phones, smart phones, personal digital assistants and wireless pagers, augmented reality devices, virtual reality devices, combinations of the same or the like. Likewise, the MNS 1710 can communicate with any type of patient monitoring device 1720 including bedside devices, body worn devices, telemetry devices, and the like. Any of these patient devices 1712 can output parameter data, trend data and/or alarms which can be provided to the MNS 1710 over the network 1708 and then re-routed by the MNS 1710 to institutions 1712, 1714, or computers thereof, and mobile clinician devices 1718.
In certain embodiments, by providing network services to the various entities shown, the MNS 1710 can provide greater reliability, security and therefore patient safety compared to existing networks in hospitals and other clinical facilities. The MNS 1710 may be implemented in one or more computing devices, such as servers, which may be geographically located, for example, in a data center, or which may be geographically disbursed, for example, in multiple data centers. The MNS 1710 can include enterprise-class networking capabilities of any state of the art or currently available data center today including, for example, load balancing features, failover features, intelligent network problem detection and resolution features, and the like.
Thus for example, one benefit that the MNS 1710 can provide in contrast with existing hospital networks is that if a switch or other network device were to fail at an existing hospital network, that network would then go down and deprive patients of necessary care. In contrast, in the MNS 1710, if a component such as a switch goes down, the MNS 1710 may be able to reroute network traffic through other switches and other components and continue or resume critical patient care services for the various institutions and devices shown.
Further, the MNS 1710 can be configured such that service level agreements (SLAs) can be provided to institutions so that guarantees of service can be met by the MNS 1710. An example SLA guarantee can be that alarms processed by the MNS 1710 can be provided to clinician devices in the institutions 1712, 1714 within a specified period of time, such as a few seconds or the like. The MNS 1710 may also provide uptime guarantees through SLAs or the like.
Moreover, by providing network services from the cloud, in certain embodiments, the MNS 1710 can provide synergistic effects that are greater than the benefits of simply moving the networking services out of the hospital and into a centralized data center. One example of a synergistic benefit of the MNS 1710 in certain embodiments is that patient profiles from different institutions or clinical facilities can be maintained by the MNS 1710 as a single patient profile. Thus, if a patient is in a first facility and has a profile that specifies alarm settings that are unique to that patient's health conditions, the MNS 1710 can store these alarm settings in the patient's profile in the cloud. If this patient subsequently is admitted to a different facility, the MNS 1710 can provide this second facility with access to the patient's profile, including the alarm settings that were previously set in the first facility. Patient profiles can enable clinicians to avoid having to re-establish useful alarm settings and/or other monitoring settings for the patient. Furthermore, the MNS 1710 can enable these patient profiles to be updated and customized at the second facility.
In addition to these features, in certain embodiments any of the data collected by the MNS 1710 can be anonymized and provided to the external entities 1716 including, for example, government agencies or research institutions for demographic and healthcare research purposes, additional examples of which are described below with respect to
Turning to
The MNS 1810 includes, for example, a network management module 1802. The network management module 1802 can manage network communications with other networks, including networks in hospitals and other facilities as well as communications with mobile patient devices and clinician devices. For example, the network management module 1802 can communicate with devices in hospitals and outside of hospitals, or inside of facilities and outside of facilities. The network management module 1802 can provide the networking services described above with respect to
The MNS 1810 also includes an EMR system 1804 that can generally store patient data from any facility, including data collected from patient monitoring devices in patients' homes or while patients are mobile outside of their homes or out of facilities. For example, the EMR system 1804 can include such information as parameter values, trend values, alarm histories, patient demographic data, patient condition data including diagnoses, patient medical histories, and patient medications, among a variety of other patient data. The data in the EMR 1804 can advantageously be used by other components of the MNS 1810 as described below to improve patient care.
A clinician portal 1806 of the MNS 1810 can provide a user interface or user interfaces that can be accessed by clinicians via their clinician devices to monitor the health status of their patients for whom they are responsible. The clinician portal 1806 may, for example, be implemented in one or more web pages, mobile applications, or other network applications and may provide information about the wellness or relative wellness of each patient.
In one embodiment, a wellness score or index is computed for some patients by a risk analysis system 1808 of the MNS 1810, and the clinician portal 1806 can depict these wellness indices among other parameter data, trend data and alarms for patients. In one embodiment, the clinician portal 1806 facilities triaging patients by providing functionality for patients to be ordered or ranked based on their wellness scores or indices as computed by the risk analysis system 1808. Example features for computing wellness indices or risk assessments are described in U.S. Pub. No. 2014/0077956, filed Sept. 18, 2013, titled “Intelligent Medical Network Edge Router,” the disclosure of which is hereby incorporated by reference in its entirety. For example, the risk analysis system 1808 can take into two or more parameters, such as any combination of the following parameters: oxygen saturation (e.g., SpO2), respiratory rate, pulse rate, heart rate, total hemoglobin level, methemoglobin, carboxyemoglobin, blood pressure, ECG output, encephalography output, or the like. The risk analysis system 1808 can combine data from such parameters and reduce this data to a single value or data representation of the combination of those parameters. The single value may be, for example, an index or score that is on a scale of 0 to 10, where 10 may represent a most healthy state, while 0 may represent a least healthy state. Thus, such scores could be used to rank the relative health state or acuity of patient sicknesses and such numerical rankings can be output for presentation to clinicians in the clinician portal 1806, thereby enabling clinicians to quickly triage patients.
In certain embodiments, the risk analysis system 1808 also leverages aspects of the cloud-based infrastructure of the MNS 1810 to improve the wellness index calculation. For example, the risk analysis system 1808 may be able to access patient profile data from the MNS 1810 that comes from previous hospital visits or other clinical facility visits from a single facility or multiple facilities to compute historical wellness indices or to compute a current wellness index. The risk analysis system 1808 can also personalize the wellness index based on patient attributes stored in the EMR system 1804. For example, the risk analysis system 1808 can personalize which parameters are weighted more heavily in the combination of parameters that are output as a wellness index based on previous patient conditions listed in EMR system 1804. In currently available systems, different institutions typically do not share their EMR data, and EMRs therefore cannot be used to correlate patient data from multiple institutions together and thereby improve risk analysis and wellness indices. However, such advantages can be made possible in certain embodiments by the centralized cloud nature of the MNS 1810.
The MNS 1810 also includes a patient profile manager 1811. The patient profile manager 1811 can manage patient profiles, which can include information about patient demographics, patient alarm settings, including alarm settings from previous visits to potentially multiple different facilities, patient conditions and so forth, and example features of which are described in greater detail below with respect to
The MNS 1810 also includes an early warning system 1816. The early warning system 1816 can issue early warning alarms based on parameter measurements, indices such as the wellness index or other indices. The early warning system 1816 can look for patterns in patients to facilitate detecting never events, including events that should occur never or rarely, like a patient dying in bed without any intervention, particularly when a patient is home and would not ordinarily be under the care of a hospital or have access to a system like the risk analysis system 1808 or the early warning system 1816.
An escalation module 1818 of the MNS 1810 can provide functionality for escalating alarms from a first or primary care provider to a second or subsequent care provider in case the primary care provider is unavailable. However, the escalation module 1818 may also provide additional functionality such as obtaining information from a remote primary care provider and providing this information to a secondary local care provider who is local to the patient and can therefore intervene using the information provided by the first care provider.
An information exchange system 1820 of the MNS 1810 can facilitate communicating information about patients to government or research institutions 1718 described above with respect to
Further, the data provided by the information exchange system 1820 can be valuable to government agencies or research institutions to determine the effects of local conditions on health conditions. It may be discovered, for instance, that patients that go to a specific facility or set of facilities in a region are afflicted with disease related to nearby coal mining which can be ascertained by research institution or a government agency that has responsibility over such activities. Accordingly, the information exchange system 1820 can provide value data that can provide reports that can be used by external entities to improve patient care.
A journaling module 1822 of the MNS 1810 can capture clinician interactions with medical devices that are in the institutions and/or that are in patients' homes or that are body worn in mobile situations. The interactions can include any type of button press, alarm setting change, RFID tag interaction, or the like and can be recorded for the purposes of determining clinician response times to alarms or other measures of the quality of a clinician's care. The journaling module 1822 can further leverage the centralized monitoring capabilities of the MNS 1810 to compare the quality of care as journaled or otherwise calculated amongst different institutions as an apples-to-apples comparison because some or all of the data from these institutions can be provided to the centralized MNS 1810.
Further, the journal module 1822 can facilitate comparing the quality of care between different units in a hospital or other facility including different floors or groups of clinicians or shifts, or the like. The journal module 1822 can also facilitate comparing similar groups amongst different facilities, such as an ICU group in two different facilities, and can thereby enable an organization to identify gaps or deficiencies of care in different facilities that can be corrected. This information can be provided in real time or near-real time so that adverse patient care outcomes can be quickly addressed, in contrast to the past where information about quality of care is often analyzed well after an adverse care event has occurred (or even after a patient has been discharged). Further embodiments of journaling and detecting clinician interactions with devices (including via RFID tags) are described in greater detail in U.S. Pub. No. 2014/0077956, filed Sept. 18, 2013, titled “Intelligent Medical Network Edge Router,” the disclosure of which is hereby incorporated by reference in its entirety.
A telemedicine module 1824 of the MNS 1810—an embodiment of the telemedicine system described above—can facilitate telecommunications between clinicians and patients, including telepresence communications where clinicians can diagnosis, treat, or otherwise attend to the needs of patients remotely using audio visual systems or the like. For instance, the telemedicine module 1824 can facilitate audio and/or video communications between patients and clinicians. For example, using telemedicine software in a patient device, a patient can connect to the telemedicine module 1824 to communicate with a clinician using similar telemedicine software on the clinician's device. The telemedicine module 1824 may implement any audio and/or video protocols, including voice over IP (VoIP) protocols, to facilitate telemedicine communications between patients and clinicians. Yet in other embodiments, the telemedicine module can be implemented apart from the other features of the MNS. For example, telemedicine functionality described herein can be implemented through a server dedicated to telemedicine functionality, rather than the full panoply of functionality available through the MNS. Or, patient devices may perform point-to-point connections directly with clinician devices (and vice versa) using available networking protocols.
The telemedicine process 1900 may be implemented at least in part by the telemedicine system or telemedicine module 1824, described above. Further, in an embodiment, the telemedicine process 1900 may be implemented using any of the patient monitors described herein. For example, the telemedicine process 1900 could be implemented by the pulse oximeter 300 of
In one embodiment, the device or devices implementing the telemedicine process 1900 need not be a dedicated patient monitor but instead can be an electronic device capable of executing software on a hardware processor that performs monitoring functions. Thus, for example, a phone, tablet, laptop, desktop computer, television, augmented reality device, virtual reality device, or the like can implement the remote diagnostic process 1900. For example, telemedicine software stored as program instructions in a memory of any such device can perform the telemedicine process 1900. This telemedicine software (not shown) can communicate with similar telemedicine software in a clinician device and optionally may do so through the telemedicine module 1824 of the MNS 1710/1810.
Referring again to
At block 1904, the telemedicine process 1900 measures the physiological parameter using the sensor. For example. software stored in the patient monitor or electronic device can access physiological signals output by the sensor and can process those physiological signals to calculate the physiological parameter or a plurality of physiological parameters. For example, the pulse oximeter 300 of
Some examples of physiological parameters that may be calculated include oxygen saturation, pulse rate, perfusion index, pleth variability index (PVI), respiration rate, electrocardiogram parameters (ECG), electroencephalography parameters (EEG), blood pressure, temperature, as well as any other parameters described elsewhere herein. This list is not inclusive, as other physiological parameters may be measured and other types of non-invasive sensors may be used. Furthermore, in some embodiments, invasive or minimally invasive sensors may be used such as a finger-prick glucose sensor.
At block 1906, the process 1900 determines whether to obtain a reading from another sensor, and if so, loops back to block 1902. Otherwise, the process 1900 continues on to block 1908. For instance, if the process 1900 first displays instructions for using an optical sensor and then determines that a blood pressure measurement should be taken, the process 1900 loops back from block 1906 to block 1902. There, the process 1900 outputs instructions for using the blood pressure sensor and may then obtain the measurement from the blood pressure sensor in block 1904. The process 1900 may similarly loop back through blocks 1902 and 1904 to obtain temperature measurements and/or other measurements. In some embodiments, a single measurement is obtained, or a single non-invasive sensor is used from which multiple measurements may be obtained.
Although not shown, the process 1900 may also output the parameters calculated based on the measurements received or physiological signals received for display on the patient device or electronic device. Some examples of displays corresponding to the process 1900 are described below with respect to
At block 1908, the process 1900 outputs a list of available clinicians. The list can include a list of local or remote doctors or clinicians. While in one sense, all clinicians may be remote to the patient in the sense that the patient device communicates with the clinicians over the network, local clinicians can be geographically closer to the patient than remote clinicians. The list of available clinicians may be generated based on publicly available information or information obtained from an insurance carrier of the patient such that the list of clinicians may include clinicians that are in a plan provided by the patient's insurer. Or alternatively, the list can include any clinicians who have signed up or otherwise opted to participate in a telemedicine program. The list may also include solely clinicians available to consult that moment, rather than all clinicians. The list may further include wait times for consulting with a particular clinician.
At block 1910, the process 1900 receives a user selection of a clinician from the list, and at block 1912, transmits the physiological parameter measurement or measurements to the clinician over a network (which may include the Internet). The transmission of the physiological parameter measurement or measurements to the clinician may be in the form of a message split into a plurality of packets sent over a network that implements any of the currently available network protocols today, such as the TCP/IP protocol. The parameters may be transmitted from the patient device through the MNS 1710/1810 described above and then provided to the clinician device. Alternatively, the parameter measurements may be provided directly from the patient device to the clinician device over the network.
At block 1914, the process 1900 initiates a telemedicine session with a clinician via audio and/or video. This can be a one-way or a two-way video session where the clinician and the patient see video of each other using currently available video communications protocols. The patient device may access video from the clinician and vice versa by way of accessing the telemedicine module 1824 described above. In this session, the clinician may have access to the physiological parameters measured previously. The clinician may use his or her professional skills to analyze the measured parameters. The clinician can talk with the patient about the measured parameters and about symptoms the patient is having in order to arrive at a diagnosis and optionally provide a prescription for the patient.
As described above, the telemedicine software installed on the clinician's device can enable the clinician to communicate with telemedicine software installed on the patient's device. The telemedicine software may be a dedicated application, such as a mobile application, or may be a web application accessible by a browser (or may be a combination dedicated and web application). During the initiation of the telemedicine session at block 1910, the telemedicine software on the patient's device may communicate a request to initiate a telemedicine session to the telemedicine software on the clinician's device. At the clinician's device, the telemedicine software may receive this communication and notify the clinician (e.g., audibly and/or visually) that the patient wishes to communicate with the clinician.
The telemedicine software may provide the clinician with the option (e.g., via a user interface) to accept or decline to communicate with the patient. In the event that the clinician uses the telemedicine software to decline the telemedicine session, the software may provide the clinician with an option to refer the patient to another clinician. If the clinician declines, for example, by selecting a user interface control from a user interface that provides the ability to do so, a decline message may be sent back from the clinician device to the patient device. If a decline message is received at the patient device, the telemedicine software at the patient device may output the decline message via a user interface.
However, in the depicted embodiment, at block 1916, the clinician provides a diagnosis and prescription, which are received at the patient device. The diagnosis may be received in the form of a message, and the prescription may be received in the form of a message. In addition, in some embodiments the prescription is sent directly from the clinician device to a pharmacy, where it may be filled and picked up or mail ordered to the patient. This prescription message, or any of the messages described herein, may also be communicated through the MNS 1710/1810.
Turning to
Each of the user interfaces shown includes one or more user interface controls that can be selected by a user, for example, using a browser or other application software (such as a mobile application). Thus, each of the user interfaces shown may be output for presentation by electronic hardware as graphical user interfaces, which may optionally include a browser or any other application software installed thereon that outputs the user interfaces. The user interface controls shown are merely illustrative examples and can be varied in other embodiments. For instance, any of the user interface controls shown may be substituted with other types of user interface controls that provide the same or similar functionality. Some examples of user interface controls that may be used include buttons, dropdown boxes, select boxes, text boxes or text fields, checkboxes, radio buttons, toggles, breadcrumbs (e.g., identifying a page or interface that is displayed), sliders, search fields, pagination controls, tags, icons, tooltips, progress bars, notifications, message boxes, image carousels, modal windows (such as pop-ups), date and/or time pickers, accordions (e.g., a vertically stacked list with show/hide functionality), and the like. Additional user interface controls not listed here may be used. Further, user interface controls may be combined or divided into other sets of user interface controls such that similar functionality or the same functionality may be provided with very different looking user interfaces. Moreover, each of the user interface controls may be selected by a user using one or more input options, such as a mouse, touch screen input (e.g., finger or pen), game controller, or keyboard input, among other user interface input options. Although each of these user interfaces are shown implemented in a mobile device, the user interfaces or similar user interfaces can be output by any computing device, examples of which are described above.
In the depicted embodiment, each of the user interfaces shown is in the form of a tablet or phone display but may be implemented as different sized screens if used with a different type of patient device such as a dedicated patient monitor. The size may or may not be changed if used with a dedicated patient monitor. Each of the screens shown is a touchscreen in the depicted embodiment and therefore receives input from user touch, performing actions corresponding to those inputs. Touchscreens are optional, and other forms of input may be used in addition to or instead of a touchscreen.
Turning specifically to
The patient device may automatically detect when the sensor has been connected to the patient and connected to the monitor. In another embodiment, the user interface 2000 can include a user interface control (such as a button) that a user can select (e.g., press) to indicate that the user has placed the sensor in the indicated location, thereby informing the patient device to begin monitoring using that sensor. Once the user interface control is selected, the patient device may begin monitoring the output of the sensor and calculating one or more physiological parameters based on the sensor output.
Turning to
Upon selection of the user interface control 2120, a user interface such as the user interface 2200 of
The temperature sensor used may be one that is specifically provided for use with the patient monitor or may be a generic temperature sensor in other embodiments. The sensor may be wireless or wired and may communicate temperature measurements directly to the patient device. In another embodiment, the patient device outputs another user interface (not shown) that includes a text box that the patient can use to input the temperature reading into manually.
Turning to
Turning to
A user interface control 2420 in the form of a button provides the patient with the opportunity to view a list of clinicians. Selecting this control can cause a user interface 2500 shown in
The clinician may have a substantially similar display as that shown or a different display than the patient. For instance, the clinician's display may include a larger view of the patient and an inset view of the clinician. The clinician's user interface may also provide the clinician with access to an electronic medical record of the patient to view historical data obtained from the patient.
Turning to
In still other embodiments, the telemedicine system described may be implemented in a kiosk at or near a pharmacy. In such an embodiment, instead of the prescription being sent to the user's current pharmacy or a pharmacy of his or her choosing, the telemedicine system can send the prescription to the pharmacy at or near the kiosk. Of course, the kiosk may give the user the option to send the prescription to another pharmacy in other embodiments. For instance, the telemedicine system may output a user interface that includes a button (or the like) that says “send prescription here,” as well as optionally another button (or the like) that says “choose pharmacy.”
In certain embodiments, the telemedicine software at the clinician device can alert the clinician that one or more of the measurements should be re-run. As discussed above, the signal quality of some measurements may be low in certain circumstances. The telemedicine software at the patient device can convey signal quality data to the clinician device, or can convey an indication that the signal quality is low and thus, a measurement should be re-taken. The clinician can ask the patient to re-run one or more measurements to obtain better data. In another embodiment, the telemedicine software at the patient device can automatically analyze signal quality data and alert the patient to re-take one or more measurements.
As described above, the telemedicine software installed in the patient device can provide a user with instructions for using a noninvasive sensor or sensors. In some embodiments, these instructions may be in the form of video, rather than (or in addition to) in the form of images and text as described above. The telemedicine software may include storage videos describing various aspects of how to use one or more noninvasive sensors. The storage videos can include videos instructing a user had to set up a sensor, how to take a reading with the sensor, and what to do if a sensor error occurs. Such error handling videos may be automatically activated if monitoring software in the patient device detects an error condition with the sensor.
For example, if a sensor probe is misaligned on the patient or falls off of the patient, the patient monitoring software in the patient device can detect this probe misalignment or probe off condition. Any suitable algorithm for detecting probe misalignment or probe off conditions may be used, as are currently available in the art. The patient monitoring software can notify the telemedicine software of this error condition. In response, the telemedicine software can output a message on the display of the patient device. The message may be a text message, an image, or a video instructing the patient how to address the error, such as how to properly position the sensor.
Images or videos used by the telemedicine software may be stored in different versions to match the age, gender, and/or ethnicity of the patient to promote patient comfort with the telemedicine software. For example, male, female, child, adult, senior, and different ethnic varieties of videos or images may be included. Likewise, text of the software output to the user may be presented in any number of different languages, which may be user-selectable.
As a result of the text, images, or video output by the telemedicine software, the telemedicine software can give the user sufficient information to take the necessary steps at home or away from the hospital to obtain accurate measurements to send to a doctor for review.
The information sent from the telemedicine software in the patient device may be provided to the doctor either live or off-line. In other words, the live telemedicine session described above is optional, and in another embodiment, the measurements obtained from the telemedicine module may be sent over a network to a clinician, who may review the measurements at a separate time and message the patient regarding the clinician's diagnosis instead of doing a live video session. In one embodiment that employs this off-line feature, the telemedicine software may also output one or more text input fields (such as text boxes) they give the patient the ability to describe symptoms that are bothering the patient so as to enable the clinician to make a better-informed diagnosis. Just as in the live telemedicine session embodiments described above, the clinician can transmit, from the clinician device, a prescription to the patient's pharmacy and/or directly to the patient.
Moreover, in one embodiment, the telemedicine software on the patient device can include audio or video recording functionality that records a patient's description of his or her condition. The telemedicine software can store this audio or video and transmit it to the clinician device, so that the clinician can review it asynchronously, e.g., at a different time instead of live.
The process 2800 can monitor physiological parameter values, including any of the parameters discussed herein, and determine whether those parameter values indicate that CCHD rescreening would be desirable. If screening was not previously performed, the process 2800 may have a similar effect in recommending screening based on measured physiological parameter values.
At block 2802, where a process 2800 receives and processes a non-invasive sensor signal to measure a physiological parameter. Any physiological parameter discussed herein may be used, such as oxygen saturation. At block 2804, based on a value of the parameter, the process 2800 determines whether to recommend CCHD screening or rescreening. If not, the process 2800 loops back to block 2802, where the patient device continues to monitor physiological signals obtained from the non-invasive sensor.
However, if screening of CCHD is recommended, then the process 2800 moves on to block 2806, where the process 2800 notifies one or more clinicians that CCHD screening is recommended. If a clinician then instructs CCHD screening to be performed at block 2808, then at block 2810 CCHD screening is performed using any of the methods described herein. Otherwise, the process 2800 loops back to block 2802, where the patient's physiological parameters continue to be measured.
The process 2800 can be used in the context of a computing environment 2900 shown in
The patient device 300 is an example representation of any of the patient devices discussed herein. The gateway 2910 may be a server or appliance that collects data from multiple patient monitors and forwards that data to the EMR 2920. The EMR 2920 is an example electronic medical record database that stores patient medical data. While an EMR is illustrated in the example of
The patient device 300 can be in communication with one or more non-invasive sensors coupled to a patient (not shown). The patient device 300 can be used for continuous or spot check monitoring of one or more physiological parameters. The patient device 300 may include hardware and software that processes physiological signals received from the one or more non-invasive sensors to determine whether the patient is a candidate for a CCHD screening or rescreening, as set forth in the process 2800.
Commonly, many infants are screened for CCHD initially about 24 hours after birth. While many infants may pass the test, at some point in time later, an infant's condition may deteriorate, indicating that the infant should be rescreened. Thus, the patient device 300 can look for such conditions. One example of such a condition is when the infant's oxygen saturation level drops below a certain value, for example 95%. With reference again to the process 2800 of
This recommendation may be provided to clinicians in one or more ways. As shown, a recommendation 2902 to rescreen for CCHD can be displayed on the patient device 300. In addition, the patient monitor 300 can communicate a recommendation to rescreen to the hospital system 2930 across the network so that clinicians not close to the patient monitor can be informed. The recommendation can also be provided directly to clinician devices (see, e.g.,
The recommendation provided to the hospital system 2930 can pass through the gateway 2910 to the EMR 2920 to the hospital system 2930, or directly from the gateway 2910 to the hospital system 2930. The hospital system 2930, upon receipt of the recommendation, which can forward this recommendation on to the nurse's station system 2940. The nurse's station system 2940 receives the recommendation from the hospital system 2930 and may output the recommendation on a display 2942. The display 2942 includes data 2946 corresponding to a plurality of patients as well as detailed data 2948 corresponding to a specific patient. The screening recommendation 2944 corresponds to the detailed data 2948 for the particular patient in this embodiment.
The recommendation 2944 may be in the form of a popup or other user interface control, and it may be selectable such as by a mouse or a touch input. Selection of the recommendation 2944 may cause the display 2942 to show data that went into the screening recommendation, such as the oxygen saturation, pulse rate, profusion index or respiratory rate value or values that caused the patient device 300 to recommend CCHD screening. By supplying these values along with the recommendation, the patient device 300 can enable a nurse at the nurse's station system 2940 to evaluate whether or not to perform CCHD screening or rescreening.
The nurse or other clinician may determine the CCHD screening is warranted and send a notification from the nurse's station system 2940 to the patient device 300 and/or to a clinician device or devices over the network (not shown) to enable one or more clinicians to participate in CCHD screening or rescreening.
Alternatively, the hospital system 2930 can automatically schedule a rescreening in response to receiving the rescreening recommendation from the patient device 300. The hospital system 2930 can communicate the scheduled rescreening to the nurse's station system 2940, which can output the scheduled rescreening on the display 2942.
By providing the user interface 3000, the patient device or nurse's station system can advantageously provide control over what data is sent to the EMR. Some screening results may be poor results, for example, due to movement or crying of the patient. Thus, it may be undesirable to store the resulting screening data in the EMR, whereas other results may represent more valid results that may be desirable to store in the EMR.
The process 2800, and other similar process as described herein, can be also used in the context of a computing environment 3200 shown in
In various implementations, the data aggregator/translator 3202 may be a server or appliance (or other appropriate computing device) that communicates with the one or more gateways and the EMR. In some implementations of the computing environment 3200, the nurse's station 2940 and/or the hospital system 2930 may be in direct communication (either wired or wireless, or both) with the on-site gateway 2910, and may thereby communicate with the EMR 2920 via the data aggregator/translator 3202 and the gateway 2910. In some implementations, as described above, the EMR 2920 may comprise any database system or data ingestion layer, such as a national database system, or the like. Further, as described above, in some implementations, the hospital system 2930 (and including the nurse's station system 2940) are optional or not included, and the patient device 300, gateway(s) 2910, data aggregator/translator 3202, and EMR 2920 function as otherwise described herein.
In the computing environment 3200, multiple on-site gateways (e.g., gateways 2910 and 3204) may each receive data from one or more patient devices at their respective sites, and may then each pass on patient data to a data aggregator/translator 3202, which may be located remotely from the sites, or in some implementations, close to one or more of the sites. In this implementation, the gateways may advantageously be lower powered (e.g., with regard to processing power, energy needs, storage needs, etc.) computing devices as compared to the data aggregator/translator 3202, as each of the gateways are only tasked with gathering and forwarding data from a relatively small number of patient devices. Advantageously, lower powered gateways are more easily and inexpensively replaceable as compared to the data aggregator/translator 3202, which may be more complex and have higher power requirements (e.g., with regard to processing power, energy needs, storage needs, etc.) so as to gather data from multiple gateways. Such an arrangement provides a significant efficiency and maintenance advantage as the gateways, which may be located in potentially remote locations, can be easily replaceable, while the data aggregator/translator 3202, which may be located in a more central location, can provide a single computing device to handle a majority of data collection and communication with the EMR 2920.
In various implementations, one or more data aggregators/translators 3202 may be geographically distributed, and each of the data aggregators/translators 3202 may communicate with a set of on-site gateways (e.g., gateways 2910 and 3204) that are located relatively near the respective one or more data aggregators/translators 3202. Each of the one or more data aggregators/translators 3202 may then communicate with the EMR 2920.
As mentioned above, unique patient identifiers may be associated with screening data.
In some implementations, patient IDs may be validated by the patient device 300 (or another device in communication with the patent device 300). Validation of patient IDs may be accomplished by applying one or more validation rules or formulas to input patient IDs. Such validation rules may be provided via one or more validator files, which rules and/or files may be digitally signed such that only signed, authenticated files can be installed on the patent device 300. The validation rules may include, for example, one or more of, or any combination of: checking for correct checksum values, checking for certain digits being within allowable ranges, checking for a correct format, checking for a correct number of digits, and/or the like. In some implementations, the validation rules may be configurable (e.g., by a user or administrator), such that they may be customized per-device, per-site (e.g., for differing patient ID characteristics at different locations), and/or the like. Customization of validation rules may be accomplished via manual input at individual devices, via electronic input (e.g., download from a memory device) at individual devices, via download or configuration through a network (e.g., via a computing device communicating with multiple patient devices via a hospital network), any combination of the foregoing, and/or the like. In some implementations, the user is notified if an input patient ID does not validate. In some implementations, the user may optionally bypass a validation error (e.g., in an emergency situation). In some implementations, patient IDs may be obtained via automated functionality, such as scanning of a barcode on a patient wristband, facial recognition, or the like.
Patient data (e.g., CCHD screening results and/or any other patient data) transmitted from the patient device 300 to the gateway 2910, then to the data aggregator/translator 3202, and then to the EMR 2920, may, for example, be associated with the input patient ID(s). The patient data may further be associated with a timestamp and/or other appropriate data properties or metadata. The gateway 2910 and/or the data aggregator/translator 3202 may store (or temporarily store) and/or keep track of which items of patient data have been transmitted from the patient device 300. Such tracking may advantageously enable deduplication of patient data. For example, if the patient device transmits the same patient data multiple times (e.g., in the event of communication loss, etc.) the gateway 2910 and/or the data aggregator/translator 3202 may compare the transmitted data to a log of previously received patient data, and discard any patient data that was previously received. In another example, if the gateway 2910 transmits the same patient data multiple times (e.g., which may be stored, and/or which may be re-transmitted in the event of communication loss, etc.) the data aggregator/translator 3202 may compare the transmitted data to a log of previously received patient data, and discard any patient data that was previously received. The comparison may be based on, for example, patient ID(s), timestamps, etc. In an implementation, the comparison and deduplication of patient data is done at the data aggregator/translator 3202, rather than at the gateway 2910. In this implementation, advantageously (and as described above) the gateway may be made a simpler and lower powered computing device, that may be easily replaceable. For example, in the event of failure of the gateway, the gateway may be easily replaced without concern for loss of log data needed to perform deduplication of patient data. Rather, the replaced gateways may continue on transmitting data to the data aggregator/translator 3202, which may redundantly store a log of patient data, and perform the deduplication.
In various implementations, the data aggregator/translator 3202 may perform one or more additional processing or monitoring tasks. For example, data aggregator/translator 3202 may perform a translation of data or a format conversion from a data format used by the patient device 300 and/or the on-site gateways 2910 and 3204, to a data format recognized by the EMR 2920. In various implementations, the data translation/format conversion may be configurable, such that the data aggregator/translator 3202 may receive data in various or multiple formats, and may then output that data in various or multiple different formats. In another example, the data aggregator/translator 3202 may monitor a health or status of the on-site gateways 2910 and 3204, and may, for example, provide a notification (e.g., via EMR 2920, hospital system 2930, and/or nurse's station system 2940) if an on-site gateway is failing or has gone offline. Thus, advantageously, as a centralized device, the data aggregator/translator 3202 may be configured to report when communications with one or more gateways and/or patient devices is lost, or when patient data is no longer being received from certain sources.
Additionally, as a centralized store of patient data, including CCHD screening results from multiple sites/patient, the EMR 2920 may be used to run analyses, and generate reports, of patient data to gain insights on system-wide (e.g., across multiple sites) trends, characteristics, etc. In an implementation, a human reviewer or automated process or algorithm may determine, based on a review of patient data (e.g., at the EMR), that a re-screening for CCHD is needed. Accordingly, a message may be sent back from the EMR, through the data aggregator/translator 3202 and/or gateway 2910, and to the patient device 300 to cause the patient device 300 to indicate to a clinician that a re-screening is needed. In another implementation, the message may be provided to the nurse's station system 2940, or other appropriate device or system to notify a clinician to re-screen a patient for CCHD. In various implementations, other information may be transmitted back from the EMR to the data aggregator/translator, gateway, and/or patient device, e.g., status information, error information, success information, etc.
At block 3402, one or more user interfaces (e.g., similar to the example user interfaces of
At block 3410, the CCHD screening information, including the CCHD screening results, associated patient ID(s), and other related information, is communicated to the gateway (e.g., gateway 2910). The gateway then communicates the information to the data aggregator (e.g., data aggregator 3202), where the information may be processed and then communicated to the EMR. In general, the information transmitted among the various patient devices, gateways, and data aggregators/translators, may referred to as “patient data” and/or the like, and may include one or more of the various types of information described in the present application.
At optional block 3412, the patient device may receive a message (e.g., via the data aggregator/translator and gateway) to re-screen the patient for CCHD, in response to which the patient device may display a notification to a clinician to initiate a re-screening. In various implementations, other information may be received by the patient device, e.g., status information, error information, success information, etc.
At block 3502, the data aggregator/translator 3202 is in communication with one or more gateway devices, as generally described above. Communication may be via any suitable electronic communications method or protocol, including wired or wireless, via one or more networks, via the Internet, and/or the like.
At block 3504, the data aggregator/translator 3202 receives patient data from a gateway device (which may have been received by the gateway device from one or more patient devices), which patient data may include CCHD screening information and associated patient IDs. At block 3506, the data aggregator/translator 3202 may optionally de-duplicate the patient data, as generally described above. For example, if, based on log data, the data aggregator/translator 3202 determines that the received patient data was previously received (e.g., in the event that it is re-transmitted to the data aggregator/translator 3202 from a gateway as a result of an error in the gateway or temporary loss of communication), the received patient data may be discarded. The data aggregator/translator 3202 may also optionally re-format the patient data as appropriate for communication to the EMR.
At block 3508, the patient data is communicated to the EMR. At optional block 3510, the data aggregator/translator 3202 may receive a message to re-screen from the EMR. The message may be associated with one or more patient IDs. The message may further include an identification of the relevant patient device to which the message is to be communicated, or alternatively the data aggregator/translator 3202 may determine the relevant patient device. The data aggregator/translator 3202 may then communicate the message to the relevant patient device. In various implementations, other information may be received by the data aggregator/translator and/or the gateway, e.g., status information, error information, success information, etc.
In various implementations, other types of patient data (besides CCHD screening information) may be communicated and processed via the various systems and processes described herein. As noted above, in various implementations, communications among the various devices and systems described herein, e.g., patient device 300, gateway 2910, data aggregator/translator 3202, EMR 2920, hospital system 2930, nurse's stations system 2940, etc., may be via secure communications channels, protocols, etc.
Accordingly, the data aggregator/translator 3202 and/or the gateways 2910, 3204 may be computing systems or devices including memory/storage and one or more processing devices configured to execute computer executable program instructions.
Conditional language used herein, such as, among others, “can,” “could,” “might,” “may,” “e.g.,” and the like, unless specifically stated otherwise, or otherwise understood within the context as used, is generally intended to convey that certain embodiments include, while other embodiments do not include, certain features, elements and/or states. Thus, such conditional language is not generally intended to imply that features, elements and/or states are in any way required for one or more embodiments or that one or more embodiments necessarily include logic for deciding, with or without author input or prompting, whether these features, elements and/or states are included or are to be performed in any particular embodiment.
While certain embodiments of the inventions disclosed herein have been described, these embodiments have been presented by way of example only, and are not intended to limit the scope of the inventions disclosed herein. Indeed, the novel methods and systems described herein can be embodied in a variety of other forms; furthermore, various omissions, substitutions and changes in the form of the methods and systems described herein can be made without departing from the spirit of the inventions disclosed herein. The claims and their equivalents are intended to cover such forms or modifications as would fall within the scope and spirit of certain of the inventions disclosed herein.
This application is a continuation-in-part of U.S. patent application Ser. No. 15/681,256, filed Aug. 18, 2017, and titled “AUTOMATED CONDITION SCREENING AND DETECTION”, which application is a continuation-in-part of U.S. patent application Ser. No. 15/279,134, filed Sep. 28, 2016, and titled “AUTOMATED CCHD SCREENING AND DETECTION”, which application is a continuation of U.S. patent application Ser. No. 15/195,037, filed Jun. 28, 2016, and titled “AUTOMATED CCHD SCREENING AND DETECTION”, which application is a divisional of U.S. patent application Ser. No. 13/733,782, filed Jan. 3, 2013, and titled “AUTOMATED CCHD SCREENING AND DETECTION”, which application claims a priority benefit under 35 U.S.C. § 119 to U.S. Provisional Patent Application No. 61/583,143, filed Jan. 4, 2012, and titled “SYSTEMS AND METHODS AUTOMATING CCHD SCREENING AND DETECTION”, and U.S. Provisional Patent Application No. 61/703,132, filed Sep. 19, 2012, and titled “SYSTEMS AND METHODS AUTOMATING CCHD SCREENING AND DETECTION”. Additionally, this application claims a priority benefit under 35 U.S.C. § 119 to U.S. Provisional Patent Application No. 62/685,834, filed Jun. 15, 2018, and titled “AUTOMATED CONDITION SCREENING AND DETECTION”. The entire disclosure of each of the above items is hereby made part of this specification as if set forth fully herein and incorporated by reference for all purposes, for all that it contains. Any and all applications, if any, for which a foreign or domestic priority claim is identified in the Application Data Sheet of the present application are hereby incorporated by reference under 37 CFR 1.57.
| Number | Name | Date | Kind |
|---|---|---|---|
| 4869253 | Craig et al. | Sep 1989 | A |
| 4960128 | Gordon et al. | Oct 1990 | A |
| 4964408 | Hink et al. | Oct 1990 | A |
| 5041187 | Hink et al. | Aug 1991 | A |
| 5069213 | Polczynski | Dec 1991 | A |
| 5078714 | Katims | Jan 1992 | A |
| 5163438 | Gordon et al. | Nov 1992 | A |
| 5319355 | Russek | Jun 1994 | A |
| 5337744 | Branigan | Aug 1994 | A |
| 5341805 | Stavridi et al. | Aug 1994 | A |
| D353195 | Savage et al. | Dec 1994 | S |
| D353196 | Savage et al. | Dec 1994 | S |
| 5377676 | Vari et al. | Jan 1995 | A |
| 5398682 | Lynn | Mar 1995 | A |
| D359546 | Savage et al. | Jun 1995 | S |
| 5431170 | Mathews | Jul 1995 | A |
| 5436499 | Namavar et al. | Jul 1995 | A |
| D361840 | Savage et al. | Aug 1995 | S |
| D362063 | Savage et al. | Sep 1995 | S |
| 5452717 | Branigan et al. | Sep 1995 | A |
| D363120 | Savage et al. | Oct 1995 | S |
| 5456252 | Vari et al. | Oct 1995 | A |
| 5479934 | Imran | Jan 1996 | A |
| 5482036 | Diab et al. | Jan 1996 | A |
| 5490505 | Diab et al. | Feb 1996 | A |
| 5494043 | O'Sullivan et al. | Feb 1996 | A |
| 5533511 | Kaspari et al. | Jul 1996 | A |
| 5534851 | Russek | Jul 1996 | A |
| 5561275 | Savage et al. | Oct 1996 | A |
| 5562002 | Lalin | Oct 1996 | A |
| 5590649 | Caro et al. | Jan 1997 | A |
| 5602924 | Durand et al. | Feb 1997 | A |
| 5632272 | Diab et al. | May 1997 | A |
| 5638816 | Kiani-Azarbayjany et al. | Jun 1997 | A |
| 5638818 | Diab et al. | Jun 1997 | A |
| 5645440 | Tobler et al. | Jul 1997 | A |
| 5671914 | Kalkhoran et al. | Sep 1997 | A |
| 5685299 | Diab et al. | Nov 1997 | A |
| 5726440 | Kalkhoran et al. | Mar 1998 | A |
| D393830 | Tobler et al. | Apr 1998 | S |
| 5743262 | Lepper, Jr. et al. | Apr 1998 | A |
| 5747806 | Khalil et al. | May 1998 | A |
| 5750994 | Schlager | May 1998 | A |
| 5758644 | Diab et al. | Jun 1998 | A |
| 5760910 | Lepper, Jr. et al. | Jun 1998 | A |
| 5769785 | Diab et al. | Jun 1998 | A |
| 5782757 | Diab et al. | Jul 1998 | A |
| 5785659 | Caro et al. | Jul 1998 | A |
| 5791347 | Flaherty et al. | Aug 1998 | A |
| 5810734 | Caro et al. | Sep 1998 | A |
| 5823950 | Diab et al. | Oct 1998 | A |
| 5830131 | Caro et al. | Nov 1998 | A |
| 5833618 | Caro et al. | Nov 1998 | A |
| 5860919 | Kiani-Azarbayjany et al. | Jan 1999 | A |
| 5890929 | Mills et al. | Apr 1999 | A |
| 5904654 | Wohltmann et al. | May 1999 | A |
| 5919134 | Diab | Jul 1999 | A |
| 5934277 | Mortz | Aug 1999 | A |
| 5934925 | Tobler et al. | Aug 1999 | A |
| 5940182 | Lepper, Jr. et al. | Aug 1999 | A |
| 5987343 | Kinast | Nov 1999 | A |
| 5995855 | Kiani et al. | Nov 1999 | A |
| 5997343 | Mills et al. | Dec 1999 | A |
| 6002952 | Diab et al. | Dec 1999 | A |
| 6010937 | Karam et al. | Jan 2000 | A |
| 6011986 | Diab et al. | Jan 2000 | A |
| 6027452 | Flaherty et al. | Feb 2000 | A |
| 6036642 | Diab et al. | Mar 2000 | A |
| 6040578 | Malin et al. | Mar 2000 | A |
| 6045509 | Caro et al. | Apr 2000 | A |
| 6066204 | Haven | May 2000 | A |
| 6067462 | Diab et al. | May 2000 | A |
| 6081735 | Diab et al. | Jun 2000 | A |
| 6083172 | Baker, Jr. et al. | Jul 2000 | A |
| 6088607 | Diab et al. | Jul 2000 | A |
| 6110522 | Lepper, Jr. et al. | Aug 2000 | A |
| 6115673 | Malin et al. | Sep 2000 | A |
| 6124597 | Shehada | Sep 2000 | A |
| 6128521 | Marro et al. | Oct 2000 | A |
| 6129675 | Jay | Oct 2000 | A |
| 6144868 | Parker | Nov 2000 | A |
| 6151516 | Kiani-Azarbayjany et al. | Nov 2000 | A |
| 6152754 | Gerhardt et al. | Nov 2000 | A |
| 6157850 | Diab et al. | Dec 2000 | A |
| 6165005 | Mills et al. | Dec 2000 | A |
| 6184521 | Coffin, IV et al. | Feb 2001 | B1 |
| 6206830 | Diab et al. | Mar 2001 | B1 |
| 6229856 | Diab et al. | May 2001 | B1 |
| 6232609 | Snyder et al. | May 2001 | B1 |
| 6236872 | Diab et al. | May 2001 | B1 |
| 6241683 | Macklem et al. | Jun 2001 | B1 |
| 6253097 | Aronow et al. | Jun 2001 | B1 |
| 6255708 | Sudharsanan et al. | Jul 2001 | B1 |
| 6256523 | Diab et al. | Jul 2001 | B1 |
| 6263222 | Diab et al. | Jul 2001 | B1 |
| 6278522 | Lepper, Jr. et al. | Aug 2001 | B1 |
| 6280213 | Tobler et al. | Aug 2001 | B1 |
| 6280381 | Malin et al. | Aug 2001 | B1 |
| 6285896 | Tobler et al. | Sep 2001 | B1 |
| 6301493 | Marro et al. | Oct 2001 | B1 |
| 6308089 | von der Ruhr et al. | Oct 2001 | B1 |
| 6317627 | Ennen et al. | Nov 2001 | B1 |
| 6321100 | Parker | Nov 2001 | B1 |
| 6321110 | Ito et al. | Nov 2001 | B1 |
| 6325761 | Jay | Dec 2001 | B1 |
| 6334065 | Al-Ali et al. | Dec 2001 | B1 |
| 6343224 | Parker | Jan 2002 | B1 |
| 6349228 | Kiani et al. | Feb 2002 | B1 |
| 6360114 | Diab et al. | Mar 2002 | B1 |
| 6368283 | Xu et al. | Apr 2002 | B1 |
| 6371921 | Caro et al. | Apr 2002 | B1 |
| 6377829 | Al-Ali | Apr 2002 | B1 |
| 6388240 | Schulz et al. | May 2002 | B2 |
| 6397091 | Diab et al. | May 2002 | B2 |
| 6411373 | Garside et al. | Jun 2002 | B1 |
| 6415167 | Blank et al. | Jul 2002 | B1 |
| 6430437 | Marro | Aug 2002 | B1 |
| 6430525 | Weber et al. | Aug 2002 | B1 |
| 6463311 | Diab | Oct 2002 | B1 |
| 6470199 | Kopotic et al. | Oct 2002 | B1 |
| 6487429 | Hockersmith et al. | Nov 2002 | B2 |
| 6501975 | Diab et al. | Dec 2002 | B2 |
| 6505059 | Kollias et al. | Jan 2003 | B1 |
| 6515273 | Al-Ali | Feb 2003 | B2 |
| 6519487 | Parker | Feb 2003 | B1 |
| 6525386 | Mills et al. | Feb 2003 | B1 |
| 6526300 | Kiani et al. | Feb 2003 | B1 |
| 6534012 | Hazen et al. | Mar 2003 | B1 |
| 6541756 | Schulz et al. | Apr 2003 | B2 |
| 6542764 | Al-Ali et al. | Apr 2003 | B1 |
| 6580086 | Schulz et al. | Jun 2003 | B1 |
| 6584336 | Ali et al. | Jun 2003 | B1 |
| 6587196 | Stippick et al. | Jul 2003 | B1 |
| 6587199 | Luu | Jul 2003 | B1 |
| 6595316 | Cybulski et al. | Jul 2003 | B2 |
| 6597932 | Tian et al. | Jul 2003 | B2 |
| 6597933 | Kiani et al. | Jul 2003 | B2 |
| 6606511 | Ali et al. | Aug 2003 | B1 |
| 6632181 | Flaherty et al. | Oct 2003 | B2 |
| 6635559 | Greenwald et al. | Oct 2003 | B2 |
| 6639668 | Trepagnier | Oct 2003 | B1 |
| 6640116 | Diab | Oct 2003 | B2 |
| 6640117 | Makarewicz et al. | Oct 2003 | B2 |
| 6643530 | Diab et al. | Nov 2003 | B2 |
| 6650917 | Diab et al. | Nov 2003 | B2 |
| 6654624 | Diab et al. | Nov 2003 | B2 |
| 6658276 | Kiani et al. | Dec 2003 | B2 |
| 6661161 | Lanzo et al. | Dec 2003 | B1 |
| 6671531 | Al-Ali et al. | Dec 2003 | B2 |
| 6678543 | Diab et al. | Jan 2004 | B2 |
| 6684090 | Ali et al. | Jan 2004 | B2 |
| 6684091 | Parker | Jan 2004 | B2 |
| 6697656 | Al-Ali | Feb 2004 | B1 |
| 6697657 | Shehada et al. | Feb 2004 | B1 |
| 6697658 | Al-Ali | Feb 2004 | B2 |
| RE38476 | Diab et al. | Mar 2004 | E |
| 6699194 | Diab et al. | Mar 2004 | B1 |
| 6714804 | Al-Ali et al. | Mar 2004 | B2 |
| RE38492 | Diab et al. | Apr 2004 | E |
| 6721582 | Trepagnier et al. | Apr 2004 | B2 |
| 6721585 | Parker | Apr 2004 | B1 |
| 6725075 | Al-Ali | Apr 2004 | B2 |
| 6728560 | Kollias et al. | Apr 2004 | B2 |
| 6735459 | Parker | May 2004 | B2 |
| 6738652 | Mattu et al. | May 2004 | B2 |
| 6745060 | Diab et al. | Jun 2004 | B2 |
| 6760607 | Al-Ali | Jul 2004 | B2 |
| 6770028 | Ali et al. | Aug 2004 | B1 |
| 6771994 | Kiani et al. | Aug 2004 | B2 |
| 6788965 | Ruchti et al. | Sep 2004 | B2 |
| 6792300 | Diab et al. | Sep 2004 | B1 |
| 6813511 | Diab et al. | Nov 2004 | B2 |
| 6816241 | Grubisic | Nov 2004 | B2 |
| 6816741 | Diab | Nov 2004 | B2 |
| 6822564 | Al-Ali | Nov 2004 | B2 |
| 6826419 | Diab et al. | Nov 2004 | B2 |
| 6829378 | DiFilippo | Dec 2004 | B2 |
| 6830711 | Mills et al. | Dec 2004 | B2 |
| 6850787 | Weber et al. | Feb 2005 | B2 |
| 6850788 | Al-Ali | Feb 2005 | B2 |
| 6852083 | Caro et al. | Feb 2005 | B2 |
| 6861639 | Al-Ali | Mar 2005 | B2 |
| 6876931 | Lorenz et al. | Apr 2005 | B2 |
| 6898452 | Al-Ali et al. | May 2005 | B2 |
| 6920345 | Al-Ali et al. | Jul 2005 | B2 |
| 6931268 | Kiani-Azarbayjany et al. | Aug 2005 | B1 |
| 6934570 | Kiani et al. | Aug 2005 | B2 |
| 6939305 | Flaherty et al. | Sep 2005 | B2 |
| 6943348 | Coffin, IV | Sep 2005 | B1 |
| 6950687 | Al-Ali | Sep 2005 | B2 |
| 6956649 | Acosta et al. | Oct 2005 | B2 |
| 6961598 | Diab | Nov 2005 | B2 |
| 6970792 | Diab | Nov 2005 | B1 |
| 6979812 | Al-Ali | Dec 2005 | B2 |
| 6985764 | Mason et al. | Jan 2006 | B2 |
| 6990364 | Ruchti et al. | Jan 2006 | B2 |
| 6993371 | Kiani et al. | Jan 2006 | B2 |
| 6996427 | Ali et al. | Feb 2006 | B2 |
| 6998247 | Monfre et al. | Feb 2006 | B2 |
| 6999904 | Weber et al. | Feb 2006 | B2 |
| 7003338 | Weber et al. | Feb 2006 | B2 |
| 7003339 | Diab et al. | Feb 2006 | B2 |
| 7015451 | Dalke et al. | Mar 2006 | B2 |
| 7024233 | Ali et al. | Apr 2006 | B2 |
| 7027849 | Al-Ali | Apr 2006 | B2 |
| 7030749 | Al-Ali | Apr 2006 | B2 |
| 7039449 | Al-Ali | May 2006 | B2 |
| 7041060 | Flaherty et al. | May 2006 | B2 |
| 7044918 | Diab | May 2006 | B2 |
| 7048687 | Reuss et al. | May 2006 | B1 |
| 7067893 | Mills et al. | Jun 2006 | B2 |
| D526719 | Richie, Jr. et al. | Aug 2006 | S |
| 7096052 | Mason et al. | Aug 2006 | B2 |
| 7096054 | Abdul-Hafiz et al. | Aug 2006 | B2 |
| D529616 | Deros et al. | Oct 2006 | S |
| 7132641 | Schulz et al. | Nov 2006 | B2 |
| 7133710 | Acosta et al. | Nov 2006 | B2 |
| 7142901 | Kiani et al. | Nov 2006 | B2 |
| 7149561 | Diab | Dec 2006 | B2 |
| 7186966 | Al-Ali | Mar 2007 | B2 |
| 7190261 | Al-Ali | Mar 2007 | B2 |
| 7215984 | Diab | May 2007 | B2 |
| 7215986 | Diab | May 2007 | B2 |
| 7221971 | Diab | May 2007 | B2 |
| 7225006 | Al-Ali et al. | May 2007 | B2 |
| 7225007 | Al-Ali | May 2007 | B2 |
| RE39672 | Shehada et al. | Jun 2007 | E |
| 7239905 | Kiani-Azarbayjany et al. | Jul 2007 | B2 |
| 7245953 | Parker | Jul 2007 | B1 |
| 7254429 | Schurman et al. | Aug 2007 | B2 |
| 7254431 | Al-Ali | Aug 2007 | B2 |
| 7254433 | Diab et al. | Aug 2007 | B2 |
| 7254434 | Schulz et al. | Aug 2007 | B2 |
| 7272425 | Al-Ali | Sep 2007 | B2 |
| 7274955 | Kiani et al. | Sep 2007 | B2 |
| D554263 | Al-Ali | Oct 2007 | S |
| 7280858 | Al-Ali et al. | Oct 2007 | B2 |
| 7289835 | Mansfield et al. | Oct 2007 | B2 |
| 7292883 | De Felice et al. | Nov 2007 | B2 |
| 7295866 | Al-Ali | Nov 2007 | B2 |
| 7328053 | Diab et al. | Feb 2008 | B1 |
| 7332784 | Mills et al. | Feb 2008 | B2 |
| 7340287 | Mason et al. | Mar 2008 | B2 |
| 7341559 | Schulz et al. | Mar 2008 | B2 |
| 7343186 | Lamego et al. | Mar 2008 | B2 |
| D566282 | Al-Ali et al. | Apr 2008 | S |
| 7355512 | Al-Ali | Apr 2008 | B1 |
| 7356365 | Schurman | Apr 2008 | B2 |
| 7371981 | Abdul-Hafiz | May 2008 | B2 |
| 7373193 | Al-Ali et al. | May 2008 | B2 |
| 7373194 | Weber et al. | May 2008 | B2 |
| 7376453 | Diab et al. | May 2008 | B1 |
| 7377794 | Al Ali et al. | May 2008 | B2 |
| 7377899 | Weber et al. | May 2008 | B2 |
| 7383070 | Diab et al. | Jun 2008 | B2 |
| 7395158 | Monfre et al. | Jul 2008 | B2 |
| 7415297 | Al-Ali et al. | Aug 2008 | B2 |
| 7428432 | Ali et al. | Sep 2008 | B2 |
| 7438683 | Al-Ali et al. | Oct 2008 | B2 |
| 7440787 | Diab | Oct 2008 | B2 |
| 7454240 | Diab et al. | Nov 2008 | B2 |
| 7467002 | Weber et al. | Dec 2008 | B2 |
| 7469157 | Diab et al. | Dec 2008 | B2 |
| 7471969 | Diab et al. | Dec 2008 | B2 |
| 7471971 | Diab et al. | Dec 2008 | B2 |
| 7483729 | Al-Ali et al. | Jan 2009 | B2 |
| 7483730 | Diab et al. | Jan 2009 | B2 |
| 7489958 | Diab et al. | Feb 2009 | B2 |
| 7496391 | Diab et al. | Feb 2009 | B2 |
| 7496393 | Diab et al. | Feb 2009 | B2 |
| D587657 | Al-Ali et al. | Mar 2009 | S |
| 7499741 | Diab et al. | Mar 2009 | B2 |
| 7499835 | Weber et al. | Mar 2009 | B2 |
| 7500950 | Al-Ali et al. | Mar 2009 | B2 |
| 7509154 | Diab et al. | Mar 2009 | B2 |
| 7509494 | Al-Ali | Mar 2009 | B2 |
| 7510849 | Schurman et al. | Mar 2009 | B2 |
| 7514725 | Wojtczuk et al. | Apr 2009 | B2 |
| 7519406 | Blank et al. | Apr 2009 | B2 |
| 7526328 | Diab et al. | Apr 2009 | B2 |
| D592507 | Wachman et al. | May 2009 | S |
| 7530942 | Diab | May 2009 | B1 |
| 7530949 | Al Ali et al. | May 2009 | B2 |
| 7530955 | Diab et al. | May 2009 | B2 |
| 7563110 | Al-Ali et al. | Jul 2009 | B2 |
| 7593230 | Abul-Haj et al. | Sep 2009 | B2 |
| 7596398 | Al-Ali et al. | Sep 2009 | B2 |
| 7606608 | Blank et al. | Oct 2009 | B2 |
| 7618375 | Flaherty | Nov 2009 | B2 |
| 7620674 | Ruchti et al. | Nov 2009 | B2 |
| D606659 | Kiani et al. | Dec 2009 | S |
| 7629039 | Eckerbom et al. | Dec 2009 | B2 |
| 7640140 | Ruchti et al. | Dec 2009 | B2 |
| 7647083 | Al-Ali et al. | Jan 2010 | B2 |
| D609193 | Al-Ali et al. | Feb 2010 | S |
| D614305 | Al-Ali et al. | Apr 2010 | S |
| 7697966 | Monfre et al. | Apr 2010 | B2 |
| 7698105 | Ruchti et al. | Apr 2010 | B2 |
| RE41317 | Parker | May 2010 | E |
| RE41333 | Blank et al. | May 2010 | E |
| 7729733 | Al-Ali et al. | Jun 2010 | B2 |
| 7734320 | Al-Ali | Jun 2010 | B2 |
| 7761127 | Al-Ali et al. | Jul 2010 | B2 |
| 7761128 | Al-Ali et al. | Jul 2010 | B2 |
| 7764982 | Dalke et al. | Jul 2010 | B2 |
| D621516 | Kiani et al. | Aug 2010 | S |
| 7791155 | Diab | Sep 2010 | B2 |
| 7801581 | Diab | Sep 2010 | B2 |
| 7822452 | Schurman et al. | Oct 2010 | B2 |
| RE41912 | Parker | Nov 2010 | E |
| 7844313 | Kiani et al. | Nov 2010 | B2 |
| 7844314 | Al-Ali | Nov 2010 | B2 |
| 7844315 | Al-Ali | Nov 2010 | B2 |
| 7865222 | Weber et al. | Jan 2011 | B2 |
| 7873497 | Weber et al. | Jan 2011 | B2 |
| 7880606 | Al-Ali | Feb 2011 | B2 |
| 7880626 | Al-Ali et al. | Feb 2011 | B2 |
| 7891355 | Al-Ali et al. | Feb 2011 | B2 |
| 7894868 | Al-Ali et al. | Feb 2011 | B2 |
| 7899507 | Al-Ali et al. | Mar 2011 | B2 |
| 7899518 | Trepagnier et al. | Mar 2011 | B2 |
| 7904132 | Weber et al. | Mar 2011 | B2 |
| 7909772 | Popov et al. | Mar 2011 | B2 |
| 7910875 | Al-Ali | Mar 2011 | B2 |
| 7919713 | Al-Ali et al. | Apr 2011 | B2 |
| 7937128 | Al-Ali | May 2011 | B2 |
| 7937129 | Mason et al. | May 2011 | B2 |
| 7937130 | Diab et al. | May 2011 | B2 |
| 7941199 | Kiani | May 2011 | B2 |
| 7942824 | Kayyali et al. | May 2011 | B1 |
| 7951086 | Flaherty et al. | May 2011 | B2 |
| 7957780 | Lamego et al. | Jun 2011 | B2 |
| 7962188 | Kiani et al. | Jun 2011 | B2 |
| 7962190 | Diab et al. | Jun 2011 | B1 |
| 7976472 | Kiani | Jul 2011 | B2 |
| 7988637 | Diab | Aug 2011 | B2 |
| 7990382 | Kiani | Aug 2011 | B2 |
| 7991446 | Al-Ali et al. | Aug 2011 | B2 |
| 8000761 | Al-Ali | Aug 2011 | B2 |
| 8008088 | Bellott et al. | Aug 2011 | B2 |
| RE42753 | Kiani-Azarbayjany et al. | Sep 2011 | E |
| 8019400 | Diab et al. | Sep 2011 | B2 |
| 8028701 | Al-Ali et al. | Oct 2011 | B2 |
| 8029765 | Bellott et al. | Oct 2011 | B2 |
| 8036727 | Schurman et al. | Oct 2011 | B2 |
| 8036728 | Diab et al. | Oct 2011 | B2 |
| 8046040 | Ali et al. | Oct 2011 | B2 |
| 8046041 | Diab et al. | Oct 2011 | B2 |
| 8046042 | Diab et al. | Oct 2011 | B2 |
| 8048040 | Kiani | Nov 2011 | B2 |
| 8050728 | Al-Ali et al. | Nov 2011 | B2 |
| RE43169 | Parker | Feb 2012 | E |
| 8118620 | Al-Ali et al. | Feb 2012 | B2 |
| 8126528 | Diab et al. | Feb 2012 | B2 |
| 8128572 | Diab et al. | Mar 2012 | B2 |
| 8130105 | Al-Ali et al. | Mar 2012 | B2 |
| 8145287 | Diab et al. | Mar 2012 | B2 |
| 8150487 | Diab et al. | Apr 2012 | B2 |
| 8175672 | Parker | May 2012 | B2 |
| 8180420 | Diab et al. | May 2012 | B2 |
| 8182443 | Kiani | May 2012 | B1 |
| 8185180 | Diab et al. | May 2012 | B2 |
| 8190223 | Al-Ali et al. | May 2012 | B2 |
| 8190227 | Diab et al. | May 2012 | B2 |
| 8203438 | Kiani et al. | Jun 2012 | B2 |
| 8203704 | Merritt et al. | Jun 2012 | B2 |
| 8204566 | Schurman et al. | Jun 2012 | B2 |
| 8219172 | Schurman et al. | Jul 2012 | B2 |
| 8224411 | Al-Ali et al. | Jul 2012 | B2 |
| 8228181 | Al-Ali | Jul 2012 | B2 |
| 8229532 | Davis | Jul 2012 | B2 |
| 8229533 | Diab et al. | Jul 2012 | B2 |
| 8233955 | Al-Ali et al. | Jul 2012 | B2 |
| 8244325 | Al-Ali et al. | Aug 2012 | B2 |
| 8255026 | Al-Ali | Aug 2012 | B1 |
| 8255027 | Al-Ali et al. | Aug 2012 | B2 |
| 8255028 | Al-Ali et al. | Aug 2012 | B2 |
| 8260577 | Weber et al. | Sep 2012 | B2 |
| 8265723 | McHale et al. | Sep 2012 | B1 |
| 8274360 | Sampath et al. | Sep 2012 | B2 |
| 8280473 | Al-Ali | Oct 2012 | B2 |
| 8301217 | Al-Ali et al. | Oct 2012 | B2 |
| 8306596 | Schurman et al. | Nov 2012 | B2 |
| 8310336 | Muhsin et al. | Nov 2012 | B2 |
| 8315683 | Al-Ali et al. | Nov 2012 | B2 |
| RE43860 | Parker | Dec 2012 | E |
| 8337403 | Al-Ali et al. | Dec 2012 | B2 |
| 8346330 | Lamego | Jan 2013 | B2 |
| 8353842 | Al-Ali et al. | Jan 2013 | B2 |
| 8355766 | MacNeish, III et al. | Jan 2013 | B2 |
| 8359080 | Diab et al. | Jan 2013 | B2 |
| 8364223 | Al-Ali et al. | Jan 2013 | B2 |
| 8364226 | Diab et al. | Jan 2013 | B2 |
| 8374665 | Lamego | Feb 2013 | B2 |
| 8385995 | Al-ali et al. | Feb 2013 | B2 |
| 8385996 | Smith et al. | Feb 2013 | B2 |
| 8388353 | Kiani et al. | Mar 2013 | B2 |
| 8399822 | Al-Ali | Mar 2013 | B2 |
| 8401602 | Kiani | Mar 2013 | B2 |
| 8405608 | Al-Ali et al. | Mar 2013 | B2 |
| 8414499 | Al-Ali et al. | Apr 2013 | B2 |
| 8418524 | Al-Ali | Apr 2013 | B2 |
| 8423106 | Lamego et al. | Apr 2013 | B2 |
| 8428967 | Olsen et al. | Apr 2013 | B2 |
| 8430817 | Al-Ali et al. | Apr 2013 | B1 |
| 8437825 | Dalvi et al. | May 2013 | B2 |
| 8455290 | Siskavich | Jun 2013 | B2 |
| 8457703 | Al-Ali | Jun 2013 | B2 |
| 8457707 | Kiani | Jun 2013 | B2 |
| 8463349 | Diab et al. | Jun 2013 | B2 |
| 8466286 | Bellot et al. | Jun 2013 | B2 |
| 8471713 | Poeze et al. | Jun 2013 | B2 |
| 8473020 | Kiani et al. | Jun 2013 | B2 |
| 8483787 | Al-Ali et al. | Jul 2013 | B2 |
| 8489364 | Weber et al. | Jul 2013 | B2 |
| 8498684 | Weber et al. | Jul 2013 | B2 |
| 8504128 | Blank et al. | Aug 2013 | B2 |
| 8509867 | Workman et al. | Aug 2013 | B2 |
| 8515509 | Bruinsma et al. | Aug 2013 | B2 |
| 8523781 | Al-Ali | Sep 2013 | B2 |
| 8529301 | Al-Ali et al. | Sep 2013 | B2 |
| 8532727 | Ali et al. | Sep 2013 | B2 |
| 8532728 | Diab et al. | Sep 2013 | B2 |
| D692145 | Al-Ali et al. | Oct 2013 | S |
| 8547209 | Kiani et al. | Oct 2013 | B2 |
| 8548548 | Al-Ali | Oct 2013 | B2 |
| 8548549 | Schurman et al. | Oct 2013 | B2 |
| 8548550 | Al-Ali et al. | Oct 2013 | B2 |
| 8560032 | Al-Ali et al. | Oct 2013 | B2 |
| 8560034 | Diab et al. | Oct 2013 | B1 |
| 8570167 | Al-Ali | Oct 2013 | B2 |
| 8570503 | Vo et al. | Oct 2013 | B2 |
| 8571617 | Reichgott et al. | Oct 2013 | B2 |
| 8571618 | Lamego et al. | Oct 2013 | B1 |
| 8571619 | Al-Ali et al. | Oct 2013 | B2 |
| 8577431 | Lamego et al. | Nov 2013 | B2 |
| 8581732 | Al-Ali et al. | Nov 2013 | B2 |
| 8584345 | Al-Ali et al. | Nov 2013 | B2 |
| 8588880 | Abdul-Hafiz et al. | Nov 2013 | B2 |
| 8600467 | Al-Ali et al. | Dec 2013 | B2 |
| 8606342 | Diab | Dec 2013 | B2 |
| 8626255 | Al-Ali et al. | Jan 2014 | B2 |
| 8630691 | Lamego et al. | Jan 2014 | B2 |
| 8634889 | Al-Ali et al. | Jan 2014 | B2 |
| 8641631 | Sierra et al. | Feb 2014 | B2 |
| 8652060 | Al-Ali | Feb 2014 | B2 |
| 8663107 | Kiani | Mar 2014 | B2 |
| 8666468 | Al-Ali | Mar 2014 | B1 |
| 8667967 | Al-Ali et al. | Mar 2014 | B2 |
| 8670811 | O'Reilly | Mar 2014 | B2 |
| 8670814 | Diab et al. | Mar 2014 | B2 |
| 8676286 | Weber et al. | Mar 2014 | B2 |
| 8682407 | Al-Ali | Mar 2014 | B2 |
| RE44823 | Parker | Apr 2014 | E |
| RE44875 | Kiani et al. | Apr 2014 | E |
| 8688183 | Bruinsma et al. | Apr 2014 | B2 |
| 8690799 | Telfort et al. | Apr 2014 | B2 |
| 8700112 | Kiani | Apr 2014 | B2 |
| 8702627 | Telfort et al. | Apr 2014 | B2 |
| 8706179 | Parker | Apr 2014 | B2 |
| 8712494 | MacNeish, III et al. | Apr 2014 | B1 |
| 8715206 | Telfort et al. | May 2014 | B2 |
| 8718735 | Lamego et al. | May 2014 | B2 |
| 8718737 | Diab et al. | May 2014 | B2 |
| 8718738 | Blank et al. | May 2014 | B2 |
| 8720249 | Al-Ali | May 2014 | B2 |
| 8721541 | Al-Ali et al. | May 2014 | B2 |
| 8721542 | Al-Ali et al. | May 2014 | B2 |
| 8723677 | Kiani | May 2014 | B1 |
| 8740792 | Kiani et al. | Jun 2014 | B1 |
| 8754776 | Poeze et al. | Jun 2014 | B2 |
| 8755535 | Telfort et al. | Jun 2014 | B2 |
| 8755856 | Diab et al. | Jun 2014 | B2 |
| 8755872 | Marinow | Jun 2014 | B1 |
| 8761850 | Lamego | Jun 2014 | B2 |
| 8764671 | Kiani | Jul 2014 | B2 |
| 8768423 | Shakespeare et al. | Jul 2014 | B2 |
| 8771204 | Telfort et al. | Jul 2014 | B2 |
| 8777634 | Kiani et al. | Jul 2014 | B2 |
| 8781543 | Diab et al. | Jul 2014 | B2 |
| 8781544 | Al-Ali et al. | Jul 2014 | B2 |
| 8781549 | Al-Ali et al. | Jul 2014 | B2 |
| 8788003 | Schurman et al. | Jul 2014 | B2 |
| 8790268 | Al-Ali | Jul 2014 | B2 |
| 8801613 | Al-Ali et al. | Aug 2014 | B2 |
| 8821397 | Al-Ali et al. | Sep 2014 | B2 |
| 8821415 | Al-Ali et al. | Sep 2014 | B2 |
| 8830449 | Lamego et al. | Sep 2014 | B1 |
| 8831700 | Schurman et al. | Sep 2014 | B2 |
| 8840549 | Al-Ali et al. | Sep 2014 | B2 |
| 8847740 | Kiani et al. | Sep 2014 | B2 |
| 8849365 | Smith et al. | Sep 2014 | B2 |
| 8852094 | Al-Ali et al. | Oct 2014 | B2 |
| 8852994 | Wojtczuk et al. | Oct 2014 | B2 |
| 8868147 | Stippick et al. | Oct 2014 | B2 |
| 8868150 | Al-Ali et al. | Oct 2014 | B2 |
| 8870792 | Al-Ali et al. | Oct 2014 | B2 |
| 8886271 | Kiani et al. | Nov 2014 | B2 |
| 8888539 | Al-Ali et al. | Nov 2014 | B2 |
| 8888708 | Diab et al. | Nov 2014 | B2 |
| 8892180 | Weber et al. | Nov 2014 | B2 |
| 8897847 | Al-Ali | Nov 2014 | B2 |
| 8909310 | Lamego et al. | Dec 2014 | B2 |
| 8911377 | Al-Ali | Dec 2014 | B2 |
| 8912909 | Al-Ali et al. | Dec 2014 | B2 |
| 8920317 | Al-Ali et al. | Dec 2014 | B2 |
| 8921699 | Al-Ali et al. | Dec 2014 | B2 |
| 8922382 | Al-Ali et al. | Dec 2014 | B2 |
| 8929964 | Al-Ali et al. | Jan 2015 | B2 |
| 8942777 | Diab et al. | Jan 2015 | B2 |
| 8948834 | Diab et al. | Feb 2015 | B2 |
| 8948835 | Diab | Feb 2015 | B2 |
| 8965471 | Lamego | Feb 2015 | B2 |
| 8983564 | Al-Ali | Mar 2015 | B2 |
| 8989831 | Al-Ali et al. | Mar 2015 | B2 |
| 8996085 | Kiani et al. | Mar 2015 | B2 |
| 8998809 | Kiani | Apr 2015 | B2 |
| 9028429 | Telfort et al. | May 2015 | B2 |
| 9037207 | Al-Ali et al. | May 2015 | B2 |
| 9060721 | Reichgott et al. | Jun 2015 | B2 |
| 9066666 | Kiani | Jun 2015 | B2 |
| 9066680 | Al-Ali et al. | Jun 2015 | B1 |
| 9072474 | Al-Ali et al. | Jul 2015 | B2 |
| 9078560 | Schurman et al. | Jul 2015 | B2 |
| 9084569 | Weber et al. | Jul 2015 | B2 |
| 9095316 | Welch et al. | Aug 2015 | B2 |
| 9106038 | Telfort et al. | Aug 2015 | B2 |
| 9107625 | Telfort et al. | Aug 2015 | B2 |
| 9107626 | Al-Ali et al. | Aug 2015 | B2 |
| 9113831 | Al-Ali | Aug 2015 | B2 |
| 9113832 | Al-Ali | Aug 2015 | B2 |
| 9119595 | Lamego | Sep 2015 | B2 |
| 9131881 | Diab et al. | Sep 2015 | B2 |
| 9131882 | Al-Ali et al. | Sep 2015 | B2 |
| 9131883 | Al-Ali | Sep 2015 | B2 |
| 9131917 | Telfort et al. | Sep 2015 | B2 |
| 9138180 | Coverston et al. | Sep 2015 | B1 |
| 9138182 | Al-Ali et al. | Sep 2015 | B2 |
| 9138192 | Weber et al. | Sep 2015 | B2 |
| 9142117 | Muhsin et al. | Sep 2015 | B2 |
| 9153112 | Kiani et al. | Oct 2015 | B1 |
| 9153121 | Kiani et al. | Oct 2015 | B2 |
| 9161696 | Al-Ali et al. | Oct 2015 | B2 |
| 9161713 | Al-Ali et al. | Oct 2015 | B2 |
| 9167995 | Lamego et al. | Oct 2015 | B2 |
| 9176141 | Al-Ali et al. | Nov 2015 | B2 |
| 9186102 | Bruinsma et al. | Nov 2015 | B2 |
| 9192312 | Al-Ali | Nov 2015 | B2 |
| 9192329 | Al-Ali | Nov 2015 | B2 |
| 9192351 | Telfort et al. | Nov 2015 | B1 |
| 9195385 | Al-Ali et al. | Nov 2015 | B2 |
| 9211072 | Kiani | Dec 2015 | B2 |
| 9211095 | Al-Ali | Dec 2015 | B1 |
| 9218454 | Kiani et al. | Dec 2015 | B2 |
| 9226696 | Kiani | Jan 2016 | B2 |
| 9241662 | Al-Ali et al. | Jan 2016 | B2 |
| 9245668 | Vo et al. | Jan 2016 | B1 |
| 9259185 | Abdul-Hafiz et al. | Feb 2016 | B2 |
| 9267572 | Barker et al. | Feb 2016 | B2 |
| 9277880 | Poeze et al. | Mar 2016 | B2 |
| 9289167 | Diab et al. | Mar 2016 | B2 |
| 9295421 | Kiani et al. | Mar 2016 | B2 |
| 9307928 | Al-Ali et al. | Apr 2016 | B1 |
| 9323894 | Kiani | Apr 2016 | B2 |
| D755392 | Hwang et al. | May 2016 | S |
| 9326712 | Kiani | May 2016 | B1 |
| 9333316 | Kiani | May 2016 | B2 |
| 9339220 | Lamego et al. | May 2016 | B2 |
| 9341565 | Lamego et al. | May 2016 | B2 |
| 9351673 | Diab et al. | May 2016 | B2 |
| 9351675 | Al-Ali et al. | May 2016 | B2 |
| 9364181 | Kiani et al. | Jun 2016 | B2 |
| 9368671 | Wojtczuk et al. | Jun 2016 | B2 |
| 9370325 | Al-Ali et al. | Jun 2016 | B2 |
| 9370326 | McHale et al. | Jun 2016 | B2 |
| 9370335 | Al-ali et al. | Jun 2016 | B2 |
| 9375185 | Ali et al. | Jun 2016 | B2 |
| 9386953 | Al-Ali | Jul 2016 | B2 |
| 9386961 | Al-Ali et al. | Jul 2016 | B2 |
| 9392945 | Al-Ali et al. | Jul 2016 | B2 |
| 9397448 | Al-Ali et al. | Jul 2016 | B2 |
| 9408542 | Kinast et al. | Aug 2016 | B1 |
| 9436645 | Al-Ali et al. | Sep 2016 | B2 |
| 9445759 | Lamego et al. | Sep 2016 | B1 |
| 9466919 | Kiani et al. | Oct 2016 | B2 |
| 9474474 | Lamego et al. | Oct 2016 | B2 |
| 9480422 | Al-Ali | Nov 2016 | B2 |
| 9480435 | Olsen | Nov 2016 | B2 |
| 9492110 | Al-Ali et al. | Nov 2016 | B2 |
| 9510779 | Poeze et al. | Dec 2016 | B2 |
| 9517024 | Kiani et al. | Dec 2016 | B2 |
| 9532722 | Lamego et al. | Jan 2017 | B2 |
| 9538949 | Al-Ali et al. | Jan 2017 | B2 |
| 9538980 | Telfort et al. | Jan 2017 | B2 |
| 9549696 | Lamego et al. | Jan 2017 | B2 |
| 9554737 | Schurman et al. | Jan 2017 | B2 |
| 9560996 | Kiani | Feb 2017 | B2 |
| 9560998 | Al-Ali et al. | Feb 2017 | B2 |
| 9566019 | Al-Ali et al. | Feb 2017 | B2 |
| 9579039 | Jansen et al. | Feb 2017 | B2 |
| 9591975 | Dalvi et al. | Mar 2017 | B2 |
| 9622692 | Lamego et al. | Apr 2017 | B2 |
| 9622693 | Diab | Apr 2017 | B2 |
| D788312 | Al-Ali et al. | May 2017 | S |
| 9636055 | Al-Ali et al. | May 2017 | B2 |
| 9636056 | Al-Ali | May 2017 | B2 |
| 9649054 | Lamego et al. | May 2017 | B2 |
| 9662052 | Al-Ali et al. | May 2017 | B2 |
| 9668679 | Schurman et al. | Jun 2017 | B2 |
| 9668680 | Bruinsma et al. | Jun 2017 | B2 |
| 9668703 | Al-Ali | Jun 2017 | B2 |
| 9675286 | Diab | Jun 2017 | B2 |
| 9687160 | Kiani | Jun 2017 | B2 |
| 9693719 | Al-Ali et al. | Jul 2017 | B2 |
| 9693737 | Al-Ali | Jul 2017 | B2 |
| 9697928 | Al-Ali et al. | Jul 2017 | B2 |
| 9717425 | Kiani et al. | Aug 2017 | B2 |
| 9717458 | Lamego et al. | Aug 2017 | B2 |
| 9724016 | Al-Ali et al. | Aug 2017 | B1 |
| 9724024 | Al-Ali | Aug 2017 | B2 |
| 9724025 | Kiani et al. | Aug 2017 | B1 |
| 9730640 | Diab et al. | Aug 2017 | B2 |
| 9743887 | Al-Ali et al. | Aug 2017 | B2 |
| 9749232 | Sampath et al. | Aug 2017 | B2 |
| 9750442 | Olsen | Sep 2017 | B2 |
| 9750443 | Smith et al. | Sep 2017 | B2 |
| 9750461 | Telfort | Sep 2017 | B1 |
| 9775545 | Al-Ali et al. | Oct 2017 | B2 |
| 9775546 | Diab et al. | Oct 2017 | B2 |
| 9775570 | Al-Ali | Oct 2017 | B2 |
| 9778079 | Al-Ali et al. | Oct 2017 | B1 |
| 9782077 | Lamego et al. | Oct 2017 | B2 |
| 9782110 | Kiani | Oct 2017 | B2 |
| 9787568 | Lamego et al. | Oct 2017 | B2 |
| 9788735 | Al-Ali | Oct 2017 | B2 |
| 9788768 | Al-Ali et al. | Oct 2017 | B2 |
| 9795300 | Al-Ali | Oct 2017 | B2 |
| 9795310 | Al-Ali | Oct 2017 | B2 |
| 9795358 | Telfort et al. | Oct 2017 | B2 |
| 9795739 | Al-Ali et al. | Oct 2017 | B2 |
| 9801556 | Kiani | Oct 2017 | B2 |
| 9801588 | Weber et al. | Oct 2017 | B2 |
| 9808188 | Perea et al. | Nov 2017 | B1 |
| 9814418 | Weber et al. | Nov 2017 | B2 |
| 9820691 | Kiani | Nov 2017 | B2 |
| 9833152 | Kiani et al. | Dec 2017 | B2 |
| 9833180 | Shakespeare et al. | Dec 2017 | B2 |
| 9839379 | Al-Ali et al. | Dec 2017 | B2 |
| 9839381 | Weber et al. | Dec 2017 | B1 |
| 9847002 | Kiani et al. | Dec 2017 | B2 |
| 9847749 | Kiani et al. | Dec 2017 | B2 |
| 9848800 | Lee et al. | Dec 2017 | B1 |
| 9848806 | Al-Ali et al. | Dec 2017 | B2 |
| 9848807 | Lamego | Dec 2017 | B2 |
| 9861298 | Eckerbom et al. | Jan 2018 | B2 |
| 9861304 | Al-Ali et al. | Jan 2018 | B2 |
| 9861305 | Weber et al. | Jan 2018 | B1 |
| 9867578 | Al-Ali et al. | Jan 2018 | B2 |
| 9872623 | Al-Ali | Jan 2018 | B2 |
| 9876320 | Coverston et al. | Jan 2018 | B2 |
| 9877650 | Muhsin et al. | Jan 2018 | B2 |
| 9877686 | Al-Ali et al. | Jan 2018 | B2 |
| 9891079 | Dalvi | Feb 2018 | B2 |
| 9895107 | Al-Ali et al. | Feb 2018 | B2 |
| 9913617 | Al-Ali et al. | Mar 2018 | B2 |
| 9924893 | Schurman et al. | Mar 2018 | B2 |
| 9924897 | Abdul-Hafiz | Mar 2018 | B1 |
| 9936917 | Poeze et al. | Apr 2018 | B2 |
| 9943269 | Muhsin et al. | Apr 2018 | B2 |
| 9949676 | Al-Ali | Apr 2018 | B2 |
| 9955937 | Telfort | May 2018 | B2 |
| 9965946 | Al-Ali | May 2018 | B2 |
| 9980667 | Kiani et al. | May 2018 | B2 |
| D820865 | Muhsin et al. | Jun 2018 | S |
| 9986919 | Lamego et al. | Jun 2018 | B2 |
| 9986952 | Dalvi et al. | Jun 2018 | B2 |
| 9989560 | Poeze et al. | Jun 2018 | B2 |
| 9993207 | Al-Ali et al. | Jun 2018 | B2 |
| 10007758 | Al-Ali et al. | Jun 2018 | B2 |
| D822215 | Al-Ali et al. | Jul 2018 | S |
| D822216 | Barker et al. | Jul 2018 | S |
| 10010276 | Al-Ali et al. | Jul 2018 | B2 |
| 10032002 | Kiani et al. | Jul 2018 | B2 |
| 10039482 | Al-Ali et al. | Aug 2018 | B2 |
| 10052037 | Kinast et al. | Aug 2018 | B2 |
| 10058275 | Al-Ali et al. | Aug 2018 | B2 |
| 10064562 | Al-Ali | Sep 2018 | B2 |
| 10086138 | Novak, Jr. | Oct 2018 | B1 |
| 10092200 | Al-Ali et al. | Oct 2018 | B2 |
| 10092249 | Kiani et al. | Oct 2018 | B2 |
| 10098550 | Al-Ali et al. | Oct 2018 | B2 |
| 10098591 | Al-Ali et al. | Oct 2018 | B2 |
| 10098610 | Al-Ali et al. | Oct 2018 | B2 |
| 10111591 | Dyell et al. | Oct 2018 | B2 |
| D833624 | DeJong et al. | Nov 2018 | S |
| 10123726 | Al-Ali et al. | Nov 2018 | B2 |
| 10123729 | Dyell et al. | Nov 2018 | B2 |
| 10130289 | Al-Ali et al. | Nov 2018 | B2 |
| 10130291 | Schurman et al. | Nov 2018 | B2 |
| D835282 | Barker et al. | Dec 2018 | S |
| D835283 | Barker et al. | Dec 2018 | S |
| D835284 | Barker et al. | Dec 2018 | S |
| D835285 | Barker et al. | Dec 2018 | S |
| 10149616 | Al-Ali et al. | Dec 2018 | B2 |
| 10154815 | Al-Ali et al. | Dec 2018 | B2 |
| 10159412 | Lamego et al. | Dec 2018 | B2 |
| 10188296 | Al-Ali et al. | Jan 2019 | B2 |
| 10188331 | Al-Ali et al. | Jan 2019 | B1 |
| 10188348 | Kiani et al. | Jan 2019 | B2 |
| RE47218 | Ali-Ali | Feb 2019 | E |
| RE47244 | Kiani et al. | Feb 2019 | E |
| RE47249 | Kiani et al. | Feb 2019 | E |
| 10194847 | Al-Ali | Feb 2019 | B2 |
| 10194848 | Kiani et al. | Feb 2019 | B1 |
| 10201298 | Al-Ali et al. | Feb 2019 | B2 |
| 10205272 | Kiani et al. | Feb 2019 | B2 |
| 10205291 | Scruggs et al. | Feb 2019 | B2 |
| 10213108 | Al-Ali | Feb 2019 | B2 |
| 10219706 | Al-Ali | Mar 2019 | B2 |
| 10219746 | McHale et al. | Mar 2019 | B2 |
| 10226187 | Al-Ali et al. | Mar 2019 | B2 |
| 10226576 | Kiani | Mar 2019 | B2 |
| 10231657 | Al-Ali et al. | Mar 2019 | B2 |
| 10231670 | Blank et al. | Mar 2019 | B2 |
| 10231676 | Al-Ali et al. | Mar 2019 | B2 |
| RE47353 | Kiani et al. | Apr 2019 | E |
| 10251585 | Al-Ali et al. | Apr 2019 | B2 |
| 10251586 | Lamego | Apr 2019 | B2 |
| 10255994 | Sampath et al. | Apr 2019 | B2 |
| 10258265 | Poeze et al. | Apr 2019 | B1 |
| 10258266 | Poeze et al. | Apr 2019 | B1 |
| 10271748 | Al-Ali | Apr 2019 | B2 |
| 10278626 | Schurman et al. | May 2019 | B2 |
| 10278648 | Al-Ali et al. | May 2019 | B2 |
| 10279247 | Kiani | May 2019 | B2 |
| 10292628 | Poeze et al. | May 2019 | B1 |
| 10292657 | Abdul-Hafiz et al. | May 2019 | B2 |
| 10292664 | Al-Ali | May 2019 | B2 |
| 10299708 | Poeze et al. | May 2019 | B1 |
| 10299709 | Perea et al. | May 2019 | B2 |
| 10299720 | Brown et al. | May 2019 | B2 |
| 10305775 | Lamego et al. | May 2019 | B2 |
| 10307111 | Muhsin et al. | Jun 2019 | B2 |
| 10325681 | Sampath et al. | Jun 2019 | B2 |
| 10327337 | Schmidt et al. | Jun 2019 | B2 |
| 10327713 | Barker et al. | Jun 2019 | B2 |
| 10332630 | Al-Ali | Jun 2019 | B2 |
| 10335033 | Al-Ali | Jul 2019 | B2 |
| 10335068 | Poeze et al. | Jul 2019 | B2 |
| 10335072 | Al-Ali et al. | Jul 2019 | B2 |
| 10342470 | Al-Ali et al. | Jul 2019 | B2 |
| 10342487 | Al-Ali et al. | Jul 2019 | B2 |
| 10342497 | Al-Ali et al. | Jul 2019 | B2 |
| 10349895 | Telfort et al. | Jul 2019 | B2 |
| 10349898 | Al-Ali et al. | Jul 2019 | B2 |
| 10354504 | Kiani et al. | Jul 2019 | B2 |
| 10357206 | Weber et al. | Jul 2019 | B2 |
| 10357209 | Al-Ali | Jul 2019 | B2 |
| 10366787 | Sampath et al. | Jul 2019 | B2 |
| 10368787 | Reichgott et al. | Aug 2019 | B2 |
| 10376190 | Poeze et al. | Aug 2019 | B1 |
| 10376191 | Poeze et al. | Aug 2019 | B1 |
| 10383520 | Wojtczuk et al. | Aug 2019 | B2 |
| 10383527 | Al-Ali | Aug 2019 | B2 |
| 10388120 | Muhsin et al. | Aug 2019 | B2 |
| D864120 | Forrest et al. | Oct 2019 | S |
| 10441181 | Telfort et al. | Oct 2019 | B1 |
| 10441196 | Eckerbom et al. | Oct 2019 | B2 |
| 10448844 | Al-Ali et al. | Oct 2019 | B2 |
| 10448871 | Al-Ali et al. | Oct 2019 | B2 |
| 10456038 | Lamego et al. | Oct 2019 | B2 |
| 10463340 | Telfort et al. | Nov 2019 | B2 |
| 10471159 | Lapotko et al. | Nov 2019 | B1 |
| 10505311 | Al-Ali et al. | Dec 2019 | B2 |
| 10524738 | Olsen | Jan 2020 | B2 |
| 10532174 | Al-Ali | Jan 2020 | B2 |
| 10537285 | Shreim et al. | Jan 2020 | B2 |
| 10542903 | Al-Ali et al. | Jan 2020 | B2 |
| 10555678 | Dalvi et al. | Feb 2020 | B2 |
| 10568553 | O'Neil et al. | Feb 2020 | B2 |
| RE47882 | Al-Ali | Mar 2020 | E |
| 10608817 | Haider et al. | Mar 2020 | B2 |
| D880477 | Forrest et al. | Apr 2020 | S |
| 10617302 | Al-Ali et al. | Apr 2020 | B2 |
| 10617335 | Al-Ali et al. | Apr 2020 | B2 |
| 10637181 | Al-Ali et al. | Apr 2020 | B2 |
| D887548 | Abdul-Hafiz et al. | Jun 2020 | S |
| D887549 | Abdul-Hafiz et al. | Jun 2020 | S |
| 10667764 | Ahmed et al. | Jun 2020 | B2 |
| D890708 | Forrest et al. | Jul 2020 | S |
| 10721785 | Al-Ali | Jul 2020 | B2 |
| 10729384 | Al-Ali et al. | Aug 2020 | B2 |
| 10736518 | Al-Ali et al. | Aug 2020 | B2 |
| 10750984 | Pauley et al. | Aug 2020 | B2 |
| D897098 | Al-Ali | Sep 2020 | S |
| 10779098 | Iswanto et al. | Sep 2020 | B2 |
| 10827961 | Iyengar et al. | Nov 2020 | B1 |
| 10828007 | Telfort et al. | Nov 2020 | B1 |
| 10832818 | Muhsin et al. | Nov 2020 | B2 |
| 10849554 | Shreim et al. | Dec 2020 | B2 |
| 10856750 | Indorf et al. | Dec 2020 | B2 |
| D906970 | Forrest et al. | Jan 2021 | S |
| 10918281 | Al-Ali et al. | Feb 2021 | B2 |
| 10932705 | Muhsin et al. | Mar 2021 | B2 |
| 10932729 | Kiani et al. | Mar 2021 | B2 |
| D916135 | Indorf et al. | Apr 2021 | S |
| D917550 | Indorf et al. | Apr 2021 | S |
| D917564 | Indorf et al. | Apr 2021 | S |
| D917704 | Al-Ali et al. | Apr 2021 | S |
| 10987066 | Chandran et al. | Apr 2021 | B2 |
| 10991135 | Al-Ali et al. | Apr 2021 | B2 |
| D919094 | Al-Ali et al. | May 2021 | S |
| D919100 | Al-Ali et al. | May 2021 | S |
| 11006867 | Al-Ali | May 2021 | B2 |
| D921202 | Al-Ali et al. | Jun 2021 | S |
| 11024064 | Muhsin et al. | Jun 2021 | B2 |
| 11026604 | Chen et al. | Jun 2021 | B2 |
| 20010034477 | Mansfield et al. | Oct 2001 | A1 |
| 20010039483 | Brand et al. | Nov 2001 | A1 |
| 20020010401 | Bushmakin et al. | Jan 2002 | A1 |
| 20020058864 | Mansfield et al. | May 2002 | A1 |
| 20020133080 | Apruzzese et al. | Sep 2002 | A1 |
| 20030013975 | Kiani | Jan 2003 | A1 |
| 20030018243 | Gerhardt et al. | Jan 2003 | A1 |
| 20030144582 | Cohen et al. | Jul 2003 | A1 |
| 20030156288 | Barnum et al. | Aug 2003 | A1 |
| 20030212312 | Coffin, IV et al. | Nov 2003 | A1 |
| 20040034293 | Kimball | Feb 2004 | A1 |
| 20040097797 | Porges et al. | May 2004 | A1 |
| 20040106163 | Workman, Jr. et al. | Jun 2004 | A1 |
| 20050055276 | Kiani et al. | Mar 2005 | A1 |
| 20050165316 | Lowery et al. | Jul 2005 | A1 |
| 20050234317 | Kiani | Oct 2005 | A1 |
| 20060073719 | Kiani | Apr 2006 | A1 |
| 20060161054 | Reuss et al. | Jul 2006 | A1 |
| 20060189871 | Al-Ali et al. | Aug 2006 | A1 |
| 20070073116 | Kiani et al. | Mar 2007 | A1 |
| 20070180140 | Welch et al. | Aug 2007 | A1 |
| 20070244377 | Cozad et al. | Oct 2007 | A1 |
| 20070282478 | Al-Ali et al. | Dec 2007 | A1 |
| 20080009754 | Chang | Jan 2008 | A1 |
| 20080064965 | Jay et al. | Mar 2008 | A1 |
| 20080071155 | Kiani | Mar 2008 | A1 |
| 20080094228 | Welch et al. | Apr 2008 | A1 |
| 20080221418 | Al-Ali et al. | Sep 2008 | A1 |
| 20080221464 | Al-Ali | Sep 2008 | A1 |
| 20090036759 | Ault et al. | Feb 2009 | A1 |
| 20090062664 | Chang et al. | Mar 2009 | A1 |
| 20090093687 | Telfort et al. | Apr 2009 | A1 |
| 20090095926 | MacNeish, III | Apr 2009 | A1 |
| 20090247984 | Lamego et al. | Oct 2009 | A1 |
| 20090275813 | Davis | Nov 2009 | A1 |
| 20090275844 | Al-Ali | Nov 2009 | A1 |
| 20100004035 | Ray et al. | Jan 2010 | A1 |
| 20100004518 | Vo et al. | Jan 2010 | A1 |
| 20100016690 | Watson et al. | Jan 2010 | A1 |
| 20100030040 | Poeze et al. | Feb 2010 | A1 |
| 20100099964 | O'Reilly et al. | Apr 2010 | A1 |
| 20100234718 | Sampath et al. | Sep 2010 | A1 |
| 20100270257 | Wachman et al. | Oct 2010 | A1 |
| 20110001605 | Kiani et al. | Jan 2011 | A1 |
| 20110028806 | Merritt et al. | Feb 2011 | A1 |
| 20110028809 | Goodman | Feb 2011 | A1 |
| 20110040197 | Welch et al. | Feb 2011 | A1 |
| 20110082711 | Poeze et al. | Apr 2011 | A1 |
| 20110087081 | Kiani et al. | Apr 2011 | A1 |
| 20110087083 | Poeze et al. | Apr 2011 | A1 |
| 20110105854 | Kiani et al. | May 2011 | A1 |
| 20110118561 | Tari et al. | May 2011 | A1 |
| 20110125060 | Telfort et al. | May 2011 | A1 |
| 20110137297 | Kiani et al. | Jun 2011 | A1 |
| 20110172498 | Olsen et al. | Jul 2011 | A1 |
| 20110208015 | Welch et al. | Aug 2011 | A1 |
| 20110213212 | Al-Ali | Sep 2011 | A1 |
| 20110230733 | Al-Ali | Sep 2011 | A1 |
| 20110237911 | Lamego et al. | Sep 2011 | A1 |
| 20110237969 | Eckerbom et al. | Sep 2011 | A1 |
| 20110288383 | Diab | Nov 2011 | A1 |
| 20110301444 | Al-Ali | Dec 2011 | A1 |
| 20120041316 | Al Ali et al. | Feb 2012 | A1 |
| 20120046557 | Kiani | Feb 2012 | A1 |
| 20120059267 | Lamego et al. | Mar 2012 | A1 |
| 20120088984 | Al-Ali et al. | Apr 2012 | A1 |
| 20120123231 | O'Reilly | May 2012 | A1 |
| 20120165629 | Merritt et al. | Jun 2012 | A1 |
| 20120179006 | Jansen et al. | Jul 2012 | A1 |
| 20120209082 | Al-Ali | Aug 2012 | A1 |
| 20120209084 | Olsen et al. | Aug 2012 | A1 |
| 20120226117 | Lamego et al. | Sep 2012 | A1 |
| 20120227739 | Kiani | Sep 2012 | A1 |
| 20120283524 | Kiani et al. | Nov 2012 | A1 |
| 20120296178 | Lamego et al. | Nov 2012 | A1 |
| 20120296183 | Kinsley et al. | Nov 2012 | A1 |
| 20120319816 | Al-Ali | Dec 2012 | A1 |
| 20120330112 | Lamego et al. | Dec 2012 | A1 |
| 20130018241 | Bezzerides et al. | Jan 2013 | A1 |
| 20130023775 | Lamego et al. | Jan 2013 | A1 |
| 20130041591 | Lamego | Feb 2013 | A1 |
| 20130045685 | Kiani | Feb 2013 | A1 |
| 20130046204 | Lamego et al. | Feb 2013 | A1 |
| 20130060147 | Welch et al. | Mar 2013 | A1 |
| 20130096405 | Garfio | Apr 2013 | A1 |
| 20130096936 | Sampath et al. | Apr 2013 | A1 |
| 20130197328 | Diab et al. | Aug 2013 | A1 |
| 20130211214 | Olsen | Aug 2013 | A1 |
| 20130243021 | Siskavich | Sep 2013 | A1 |
| 20130253334 | Al-Ali et al. | Sep 2013 | A1 |
| 20130262730 | Al-Ali et al. | Oct 2013 | A1 |
| 20130267804 | Al-Ali | Oct 2013 | A1 |
| 20130274572 | Al-Ali et al. | Oct 2013 | A1 |
| 20130296672 | O'Neil et al. | Nov 2013 | A1 |
| 20130296713 | Al-Ali et al. | Nov 2013 | A1 |
| 20130317370 | Dalvi et al. | Nov 2013 | A1 |
| 20130324808 | Al-Ali et al. | Dec 2013 | A1 |
| 20130331660 | Al-Ali et al. | Dec 2013 | A1 |
| 20130331670 | Kiani | Dec 2013 | A1 |
| 20130338461 | Lamego et al. | Dec 2013 | A1 |
| 20130345921 | Al-Ali et al. | Dec 2013 | A1 |
| 20140012100 | Al-Ali et al. | Jan 2014 | A1 |
| 20140034353 | Al-Ali et al. | Feb 2014 | A1 |
| 20140051953 | Lamego et al. | Feb 2014 | A1 |
| 20140058230 | Abdul-Hafiz et al. | Feb 2014 | A1 |
| 20140066783 | Kiani et al. | Mar 2014 | A1 |
| 20140077956 | Sampath et al. | Mar 2014 | A1 |
| 20140081100 | Muhsin et al. | Mar 2014 | A1 |
| 20140081175 | Telfort | Mar 2014 | A1 |
| 20140094667 | Schurman et al. | Apr 2014 | A1 |
| 20140100434 | Diab et al. | Apr 2014 | A1 |
| 20140114199 | Lamego et al. | Apr 2014 | A1 |
| 20140120564 | Workman et al. | May 2014 | A1 |
| 20140121482 | Merritt et al. | May 2014 | A1 |
| 20140121483 | Kiani | May 2014 | A1 |
| 20140127137 | Bellott et al. | May 2014 | A1 |
| 20140129702 | Lamego et al. | May 2014 | A1 |
| 20140135588 | Al-Ali et al. | May 2014 | A1 |
| 20140142401 | Al-Ali et al. | May 2014 | A1 |
| 20140163344 | Al-Ali | Jun 2014 | A1 |
| 20140163402 | Lamego et al. | Jun 2014 | A1 |
| 20140166076 | Kiani et al. | Jun 2014 | A1 |
| 20140171763 | Diab | Jun 2014 | A1 |
| 20140180038 | Kiani | Jun 2014 | A1 |
| 20140180154 | Sierra et al. | Jun 2014 | A1 |
| 20140180160 | Brown et al. | Jun 2014 | A1 |
| 20140187973 | Brown et al. | Jul 2014 | A1 |
| 20140194709 | Al-Ali et al. | Jul 2014 | A1 |
| 20140194711 | Al-Ali | Jul 2014 | A1 |
| 20140194766 | Al-Ali et al. | Jul 2014 | A1 |
| 20140206963 | Al-Ali | Jul 2014 | A1 |
| 20140213864 | Abdul-Hafiz et al. | Jul 2014 | A1 |
| 20140243627 | Diab et al. | Aug 2014 | A1 |
| 20140266790 | Al-Ali et al. | Sep 2014 | A1 |
| 20140275808 | Poeze et al. | Sep 2014 | A1 |
| 20140275835 | Lamego et al. | Sep 2014 | A1 |
| 20140275871 | Lamego et al. | Sep 2014 | A1 |
| 20140275872 | Merritt et al. | Sep 2014 | A1 |
| 20140275881 | Lamego et al. | Sep 2014 | A1 |
| 20140276115 | Dalvi et al. | Sep 2014 | A1 |
| 20140288400 | Diab et al. | Sep 2014 | A1 |
| 20140303520 | Telfort et al. | Oct 2014 | A1 |
| 20140316217 | Purdon et al. | Oct 2014 | A1 |
| 20140316218 | Purdon et al. | Oct 2014 | A1 |
| 20140316228 | Blank et al. | Oct 2014 | A1 |
| 20140323825 | Al-Ali et al. | Oct 2014 | A1 |
| 20140323897 | Brown et al. | Oct 2014 | A1 |
| 20140323898 | Purdon et al. | Oct 2014 | A1 |
| 20140330092 | Al-Ali et al. | Nov 2014 | A1 |
| 20140330098 | Merritt et al. | Nov 2014 | A1 |
| 20140330099 | Al-Ali et al. | Nov 2014 | A1 |
| 20140333440 | Kiani | Nov 2014 | A1 |
| 20140336481 | Shakespeare et al. | Nov 2014 | A1 |
| 20140343436 | Kiani | Nov 2014 | A1 |
| 20140357966 | Al-Ali et al. | Dec 2014 | A1 |
| 20140371548 | Al-Ali et al. | Dec 2014 | A1 |
| 20140371632 | Al-Ali et al. | Dec 2014 | A1 |
| 20140378784 | Kiani et al. | Dec 2014 | A1 |
| 20150005600 | Blank et al. | Jan 2015 | A1 |
| 20150011907 | Purdon et al. | Jan 2015 | A1 |
| 20150012231 | Poeze et al. | Jan 2015 | A1 |
| 20150018650 | Al-Ali et al. | Jan 2015 | A1 |
| 20150025406 | Al-Ali | Jan 2015 | A1 |
| 20150032029 | Al-Ali et al. | Jan 2015 | A1 |
| 20150038859 | Dalvi et al. | Feb 2015 | A1 |
| 20150045637 | Dalvi | Feb 2015 | A1 |
| 20150051462 | Olsen | Feb 2015 | A1 |
| 20150073241 | Lamego | Mar 2015 | A1 |
| 20150080754 | Purdon et al. | Mar 2015 | A1 |
| 20150087936 | Al-Ali et al. | Mar 2015 | A1 |
| 20150094546 | Al-Ali | Apr 2015 | A1 |
| 20150097701 | Muhsin et al. | Apr 2015 | A1 |
| 20150099950 | Al-Ali et al. | Apr 2015 | A1 |
| 20150099951 | Al-Ali et al. | Apr 2015 | A1 |
| 20150099955 | Al-Ali et al. | Apr 2015 | A1 |
| 20150101844 | Al-Ali et al. | Apr 2015 | A1 |
| 20150106121 | Muhsin et al. | Apr 2015 | A1 |
| 20150112151 | Muhsin et al. | Apr 2015 | A1 |
| 20150116076 | Al-Ali et al. | Apr 2015 | A1 |
| 20150126830 | Schurman et al. | May 2015 | A1 |
| 20150133755 | Smith et al. | May 2015 | A1 |
| 20150140863 | Al-Ali et al. | May 2015 | A1 |
| 20150141781 | Weber et al. | May 2015 | A1 |
| 20150165312 | Kiani | Jun 2015 | A1 |
| 20150196237 | Lamego | Jul 2015 | A1 |
| 20150196249 | Brown et al. | Jul 2015 | A1 |
| 20150201874 | Diab | Jul 2015 | A1 |
| 20150208966 | Al-Ali | Jul 2015 | A1 |
| 20150216459 | Al-Ali et al. | Aug 2015 | A1 |
| 20150230755 | Al-Ali et al. | Aug 2015 | A1 |
| 20150238722 | Al-Ali | Aug 2015 | A1 |
| 20150245773 | Lamego et al. | Sep 2015 | A1 |
| 20150245794 | Al-Ali | Sep 2015 | A1 |
| 20150257689 | Al-Ali et al. | Sep 2015 | A1 |
| 20150272514 | Kiani et al. | Oct 2015 | A1 |
| 20150351697 | Weber et al. | Dec 2015 | A1 |
| 20150351704 | Kiani et al. | Dec 2015 | A1 |
| 20150359429 | Al-Ali et al. | Dec 2015 | A1 |
| 20150366472 | Kiani | Dec 2015 | A1 |
| 20150366507 | Blank et al. | Dec 2015 | A1 |
| 20150374298 | Al-Ali et al. | Dec 2015 | A1 |
| 20150380875 | Coverston et al. | Dec 2015 | A1 |
| 20160000362 | Diab et al. | Jan 2016 | A1 |
| 20160007930 | Weber et al. | Jan 2016 | A1 |
| 20160029932 | Al-Ali | Feb 2016 | A1 |
| 20160029933 | Al-Ali et al. | Feb 2016 | A1 |
| 20160045118 | Kiani | Feb 2016 | A1 |
| 20160051205 | Al-Ali et al. | Feb 2016 | A1 |
| 20160058338 | Schurman et al. | Mar 2016 | A1 |
| 20160058347 | Reichgott et al. | Mar 2016 | A1 |
| 20160066823 | Al-Ali et al. | Mar 2016 | A1 |
| 20160066824 | Al-Ali et al. | Mar 2016 | A1 |
| 20160066879 | Telfort et al. | Mar 2016 | A1 |
| 20160072429 | Kiani et al. | Mar 2016 | A1 |
| 20160073967 | Lamego et al. | Mar 2016 | A1 |
| 20160081552 | Wojtczuk et al. | Mar 2016 | A1 |
| 20160095543 | Telfort et al. | Apr 2016 | A1 |
| 20160095548 | Al-Ali et al. | Apr 2016 | A1 |
| 20160103598 | Al-Ali et al. | Apr 2016 | A1 |
| 20160113527 | Al-Ali | Apr 2016 | A1 |
| 20160143548 | Al-Ali | May 2016 | A1 |
| 20160166182 | Al-Ali et al. | Jun 2016 | A1 |
| 20160166183 | Poeze et al. | Jun 2016 | A1 |
| 20160166188 | Bruinsma et al. | Jun 2016 | A1 |
| 20160166210 | Al-Ali | Jun 2016 | A1 |
| 20160192869 | Kiani et al. | Jul 2016 | A1 |
| 20160196388 | Lamego | Jul 2016 | A1 |
| 20160197436 | Barker et al. | Jul 2016 | A1 |
| 20160213281 | Eckerbom et al. | Jul 2016 | A1 |
| 20160228043 | O'Neil et al. | Aug 2016 | A1 |
| 20160233632 | Scruggs et al. | Aug 2016 | A1 |
| 20160234944 | Schmidt et al. | Aug 2016 | A1 |
| 20160270735 | Diab et al. | Sep 2016 | A1 |
| 20160283665 | Sampath et al. | Sep 2016 | A1 |
| 20160287090 | Al-Ali et al. | Oct 2016 | A1 |
| 20160287786 | Kiani | Oct 2016 | A1 |
| 20160296169 | McHale et al. | Oct 2016 | A1 |
| 20160310052 | Al-Ali et al. | Oct 2016 | A1 |
| 20160314260 | Kiani | Oct 2016 | A1 |
| 20160324486 | Al-Ali et al. | Nov 2016 | A1 |
| 20160324488 | Olsen | Nov 2016 | A1 |
| 20160327984 | Al-Ali et al. | Nov 2016 | A1 |
| 20160328528 | Al-Ali et al. | Nov 2016 | A1 |
| 20160331332 | Al-Ali | Nov 2016 | A1 |
| 20160367173 | Dalvi et al. | Dec 2016 | A1 |
| 20170000394 | Al-Ali et al. | Jan 2017 | A1 |
| 20170007134 | Al-Ali et al. | Jan 2017 | A1 |
| 20170007190 | Al-Ali et al. | Jan 2017 | A1 |
| 20170007198 | Al-Ali et al. | Jan 2017 | A1 |
| 20170014083 | Diab et al. | Jan 2017 | A1 |
| 20170014084 | Al-Ali et al. | Jan 2017 | A1 |
| 20170021099 | Al-Ali et al. | Jan 2017 | A1 |
| 20170024748 | Haider | Jan 2017 | A1 |
| 20170027456 | Kinast et al. | Feb 2017 | A1 |
| 20170042488 | Muhsin | Feb 2017 | A1 |
| 20170055847 | Kiani et al. | Mar 2017 | A1 |
| 20170055851 | Al-Ali | Mar 2017 | A1 |
| 20170055882 | Al-Ali et al. | Mar 2017 | A1 |
| 20170055887 | Al-Ali | Mar 2017 | A1 |
| 20170055896 | Al-Ali et al. | Mar 2017 | A1 |
| 20170079594 | Telfort et al. | Mar 2017 | A1 |
| 20170086723 | Al-Ali et al. | Mar 2017 | A1 |
| 20170143281 | Olsen | May 2017 | A1 |
| 20170147774 | Kiani | May 2017 | A1 |
| 20170156620 | Al-Ali et al. | Jun 2017 | A1 |
| 20170173632 | Al-Ali | Jun 2017 | A1 |
| 20170187146 | Kiani et al. | Jun 2017 | A1 |
| 20170188919 | Al-Ali et al. | Jul 2017 | A1 |
| 20170196464 | Jansen et al. | Jul 2017 | A1 |
| 20170196470 | Lamego et al. | Jul 2017 | A1 |
| 20170202490 | Al-Ali et al. | Jul 2017 | A1 |
| 20170224216 | Al-Ali | Aug 2017 | A1 |
| 20170224231 | Al-Ali | Aug 2017 | A1 |
| 20170224233 | Al-Ali | Aug 2017 | A1 |
| 20170224262 | Al-Ali | Aug 2017 | A1 |
| 20170228516 | Sampath et al. | Aug 2017 | A1 |
| 20170231537 | Al-Ali | Aug 2017 | A1 |
| 20170245790 | Al-Ali et al. | Aug 2017 | A1 |
| 20170251974 | Shreim et al. | Sep 2017 | A1 |
| 20170251975 | Shreim et al. | Sep 2017 | A1 |
| 20170258403 | Abdul-Hafiz et al. | Sep 2017 | A1 |
| 20170311891 | Kiani et al. | Nov 2017 | A1 |
| 20170332976 | Al-Ali et al. | Nov 2017 | A1 |
| 20170340293 | Al-Ali et al. | Nov 2017 | A1 |
| 20170360310 | Kiani et al. | Dec 2017 | A1 |
| 20180008146 | Al-Ali et al. | Jan 2018 | A1 |
| 20180013562 | Haider et al. | Jan 2018 | A1 |
| 20180014752 | Al-Ali et al. | Jan 2018 | A1 |
| 20180028124 | Al-Ali et al. | Feb 2018 | A1 |
| 20180055390 | Kiani et al. | Mar 2018 | A1 |
| 20180055430 | Diab et al. | Mar 2018 | A1 |
| 20180064381 | Shakespeare et al. | Mar 2018 | A1 |
| 20180069776 | Lamego et al. | Mar 2018 | A1 |
| 20180070867 | Smith et al. | Mar 2018 | A1 |
| 20180082767 | Al-Ali et al. | Mar 2018 | A1 |
| 20180085068 | Telfort | Mar 2018 | A1 |
| 20180087937 | Al-Ali et al. | Mar 2018 | A1 |
| 20180103874 | Lee et al. | Apr 2018 | A1 |
| 20180103905 | Kiani | Apr 2018 | A1 |
| 20180110478 | Al-Ali | Apr 2018 | A1 |
| 20180116575 | Perea et al. | May 2018 | A1 |
| 20180125368 | Lamego et al. | May 2018 | A1 |
| 20180125430 | Al-Ali et al. | May 2018 | A1 |
| 20180125445 | Telfort et al. | May 2018 | A1 |
| 20180130325 | Kiani et al. | May 2018 | A1 |
| 20180132769 | Weber et al. | May 2018 | A1 |
| 20180146901 | Al-Ali et al. | May 2018 | A1 |
| 20180146902 | Kiani et al. | May 2018 | A1 |
| 20180153442 | Eckerbom et al. | Jun 2018 | A1 |
| 20180153446 | Kiani | Jun 2018 | A1 |
| 20180153447 | Al-Ali et al. | Jun 2018 | A1 |
| 20180153448 | Weber et al. | Jun 2018 | A1 |
| 20180161499 | Al-Ali et al. | Jun 2018 | A1 |
| 20180168491 | Al-Ali et al. | Jun 2018 | A1 |
| 20180174679 | Sampath et al. | Jun 2018 | A1 |
| 20180174680 | Sampath et al. | Jun 2018 | A1 |
| 20180184917 | Kiani | Jul 2018 | A1 |
| 20180192924 | Al-Ali | Jul 2018 | A1 |
| 20180192953 | Shreim et al. | Jul 2018 | A1 |
| 20180192955 | Al-Ali et al. | Jul 2018 | A1 |
| 20180199871 | Pauley et al. | Jul 2018 | A1 |
| 20180206795 | Al-Ali | Jul 2018 | A1 |
| 20180206815 | Telfort | Jul 2018 | A1 |
| 20180213583 | Al-Ali | Jul 2018 | A1 |
| 20180214031 | Kiani et al. | Aug 2018 | A1 |
| 20180214090 | Al-Ali et al. | Aug 2018 | A1 |
| 20180218792 | Muhsin et al. | Aug 2018 | A1 |
| 20180225960 | Al-Ali et al. | Aug 2018 | A1 |
| 20180238718 | Dalvi | Aug 2018 | A1 |
| 20180242853 | Al-Ali | Aug 2018 | A1 |
| 20180242921 | Muhsin et al. | Aug 2018 | A1 |
| 20180242923 | Al-Ali et al. | Aug 2018 | A1 |
| 20180242924 | Barker et al. | Aug 2018 | A1 |
| 20180242926 | Muhsin et al. | Aug 2018 | A1 |
| 20180247353 | Al-Ali et al. | Aug 2018 | A1 |
| 20180247712 | Muhsin et al. | Aug 2018 | A1 |
| 20180253947 | Muhsin et al. | Sep 2018 | A1 |
| 20180256087 | Al-Ali et al. | Sep 2018 | A1 |
| 20180256113 | Weber et al. | Sep 2018 | A1 |
| 20180285094 | Housel et al. | Oct 2018 | A1 |
| 20180289325 | Poeze et al. | Oct 2018 | A1 |
| 20180289337 | Al-Ali et al. | Oct 2018 | A1 |
| 20180296161 | Shreim et al. | Oct 2018 | A1 |
| 20180300919 | Muhsin et al. | Oct 2018 | A1 |
| 20180310822 | Indorf et al. | Nov 2018 | A1 |
| 20180310823 | Al-Ali et al. | Nov 2018 | A1 |
| 20180317826 | Muhsin | Nov 2018 | A1 |
| 20180317841 | Novak, Jr. | Nov 2018 | A1 |
| 20180333055 | Lamego et al. | Nov 2018 | A1 |
| 20180333087 | Al-Ali | Nov 2018 | A1 |
| 20190000317 | Muhsin et al. | Jan 2019 | A1 |
| 20190000362 | Kiani et al. | Jan 2019 | A1 |
| 20190015023 | Monfre | Jan 2019 | A1 |
| 20190021638 | Al-Ali et al. | Jan 2019 | A1 |
| 20190029574 | Schurman et al. | Jan 2019 | A1 |
| 20190029578 | Al-Ali et al. | Jan 2019 | A1 |
| 20190058280 | Al-Ali et al. | Feb 2019 | A1 |
| 20190058281 | Al-Ali et al. | Feb 2019 | A1 |
| 20190069813 | Al-Ali | Mar 2019 | A1 |
| 20190069814 | Al-Ali | Mar 2019 | A1 |
| 20190076028 | Al-Ali et al. | Mar 2019 | A1 |
| 20190082979 | Al-Ali et al. | Mar 2019 | A1 |
| 20190090748 | Al-Ali | Mar 2019 | A1 |
| 20190090760 | Kinast et al. | Mar 2019 | A1 |
| 20190090764 | Al-Ali | Mar 2019 | A1 |
| 20190117070 | Muhsin et al. | Apr 2019 | A1 |
| 20190117139 | Al-Ali et al. | Apr 2019 | A1 |
| 20190117140 | Al-Ali et al. | Apr 2019 | A1 |
| 20190117141 | Al-Ali | Apr 2019 | A1 |
| 20190117930 | Al-Ali | Apr 2019 | A1 |
| 20190122763 | Sampath et al. | Apr 2019 | A1 |
| 20190133525 | Al-Ali et al. | May 2019 | A1 |
| 20190142283 | Lamego et al. | May 2019 | A1 |
| 20190142344 | Telfort et al. | May 2019 | A1 |
| 20190150800 | Poeze et al. | May 2019 | A1 |
| 20190150856 | Kiani et al. | May 2019 | A1 |
| 20190167161 | Al-Ali et al. | Jun 2019 | A1 |
| 20190175019 | Al-Ali et al. | Jun 2019 | A1 |
| 20190192076 | McHale et al. | Jun 2019 | A1 |
| 20190200941 | Chandran et al. | Jul 2019 | A1 |
| 20190201623 | Kiani | Jul 2019 | A1 |
| 20190209025 | Al-Ali | Jul 2019 | A1 |
| 20190214778 | Scruggs et al. | Jul 2019 | A1 |
| 20190216319 | Poeze et al. | Jul 2019 | A1 |
| 20190216379 | Al-Ali et al. | Jul 2019 | A1 |
| 20190221966 | Kiani et al. | Jul 2019 | A1 |
| 20190223804 | Blank et al. | Jul 2019 | A1 |
| 20190231199 | Al-Ali et al. | Aug 2019 | A1 |
| 20190231241 | Al-Ali et al. | Aug 2019 | A1 |
| 20190231270 | Abdul-Hafiz et al. | Aug 2019 | A1 |
| 20190239787 | Pauley et al. | Aug 2019 | A1 |
| 20190239824 | Muhsin et al. | Aug 2019 | A1 |
| 20190254578 | Lamego | Aug 2019 | A1 |
| 20190274635 | Al-Ali et al. | Sep 2019 | A1 |
| 20190320906 | Olsen | Oct 2019 | A1 |
| 20190374139 | Kiani et al. | Dec 2019 | A1 |
| 20190374713 | Kiani et al. | Dec 2019 | A1 |
| 20200060869 | Telfort et al. | Feb 2020 | A1 |
| 20200111552 | Ahmed | Apr 2020 | A1 |
| 20200113435 | Muhsin | Apr 2020 | A1 |
| 20200113488 | Al-Ali et al. | Apr 2020 | A1 |
| 20200113496 | Scruggs et al. | Apr 2020 | A1 |
| 20200113497 | Triman et al. | Apr 2020 | A1 |
| 20200113520 | Abdul-Hafiz et al. | Apr 2020 | A1 |
| 20200138288 | Al-Ali et al. | May 2020 | A1 |
| 20200138368 | Kiani et al. | May 2020 | A1 |
| 20200163597 | Dalvi et al. | May 2020 | A1 |
| 20200196877 | Vo et al. | Jun 2020 | A1 |
| 20200253474 | Muhsin et al. | Aug 2020 | A1 |
| 20200253544 | Belur Nagaraj et al. | Aug 2020 | A1 |
| 20200275841 | Telfort et al. | Sep 2020 | A1 |
| 20200288983 | Telfort et al. | Sep 2020 | A1 |
| 20200321793 | Al-Ali et al. | Oct 2020 | A1 |
| 20200329983 | Al-Ali et al. | Oct 2020 | A1 |
| 20200329984 | Al-Ali et al. | Oct 2020 | A1 |
| 20200329993 | Al-Ali et al. | Oct 2020 | A1 |
| 20200330037 | Al-Ali et al. | Oct 2020 | A1 |
| 20210022628 | Telfort et al. | Jan 2021 | A1 |
| 20210104173 | Pauley et al. | Apr 2021 | A1 |
| 20210113121 | Diab et al. | Apr 2021 | A1 |
| 20210117525 | Kiani et al. | Apr 2021 | A1 |
| 20210118581 | Kiani et al. | Apr 2021 | A1 |
| 20210121582 | Krishnamani et al. | Apr 2021 | A1 |
| 20210161465 | Barker et al. | Jun 2021 | A1 |
| Number | Date | Country |
|---|---|---|
| WO 2013103885 | Jul 2013 | WO |
| Entry |
|---|
| U.S. Pat. No. 9,392,945, Automated CCHD Screening and Detection, Jul. 19, 2016. |
| U.S. Pat. No. 10,349,898, Automated CCHD Screening and Detection, Jul. 16, 2019. |
| U.S. Pat. No. 10,278,648, Automated CCHD Screening and Detection, May 7, 2019. |
| U.S. Pat. No. 10,729,384, Automated Condition Screening and Detection, Aug. 4, 2020. |
| U.S. Pat. No. 8,457,707, Congenital Heart Disease Monitor, Jun. 4, 2013. |
| U.S. Pat. No. 9,687,160, Congenital Heart Disease Monitor, Jun. 27, 2017. |
| U.S. Pat. No. 10,588,518, Congenital Heart Disease Monitor, Mar. 17, 2020. |
| U.S. Appl. No. 16/425,706, Automated CCHD Screening and Detection, filed May 29, 2019. |
| U.S. Appl. No. 16/911,799, Automated Condition Screening and Detection, filed Jun. 25, 2020. |
| U.S. Appl. No. 16/818,855, Congenital Heart Disease Monitor, filed Mar. 13, 2020. |
| Kemper et al., “Strategies for Implementing Screening for Critical Congenital Heart Disease”, Pediatrics, Nov. 2011, vol. 128, No. 5, pp. e1259-e1267. |
| U.S. Appl. No, 15/195,037, Automated CCHD Screening and Detection, filed Jun. 28, 2016. |
| U.S. Appl. No. 15/681,256, Automated CCHD Screening and Detection, filed Aug. 18, 2017. |
| U.S. Appl. No. 15/634,502, Congenital Heart Disease Monitor, filed Jun. 27, 2017. |
| PCT International Search Report and Written Opinion, dated Apr. 17, 2013, re: PCT Application No. PCT/US2013/020377, application dated Jan. 4, 2013, in 15 pages. |
| PCT Preliminary Report of Patentability, dated Jul. 17, 2014, for application No. PCT/US2013/020377 in 9 pages. |
| Granelli A.D., Mellander et al., “Screening for duct-dependent congenital heart disease with pulse oximetry: A critical evaluation of strategies to maximize sensitivity”, Acta Paediatrica, 2005; 94:1590-1596, http://ww.masimo.com/pdf/Granelli_Article.pdf., 1 page downloaded and printed from the World Wide Web. |
| Koppel, Robert I et al., “Effective of Pulse Oximetry Screening for Congenital Heart Disease in Asymptomatic Newborns”, Pediatrics, 2003, vol. 111, No. 3, 451-455. |
| Hoke et al., “Oxygen saturation as a screening test for critical congenital heart disease: a preliminary study”, Pediatr Cardiol 23:403-409, 2002. |
| “Newborn Screening for CCHD, Answers and Resources for Primary Care Pediatricians”, American Academy of Pediatrics, http://www.aap.org/en-us/advocacy-and-policy/aap-health-initiatives/, printed on Jun. 6, 2017, in 8 pages. |
| “Tools and Technology to Start Your CCHD Screening Program”, Masimo Corporation, 2010-2011, in 16 pages. |
| “User Interface Elements”, http://www.usabilit.gov/how-to-and-tools/methods/user-interface-elements.html, printed on Jun. 19, 2017, in 7 pages. |
| Number | Date | Country | |
|---|---|---|---|
| 20190298270 A1 | Oct 2019 | US |
| Number | Date | Country | |
|---|---|---|---|
| 62685834 | Jun 2018 | US | |
| 61703132 | Sep 2012 | US | |
| 61583143 | Jan 2012 | US |
| Number | Date | Country | |
|---|---|---|---|
| Parent | 13733782 | Jan 2013 | US |
| Child | 15195037 | US |
| Number | Date | Country | |
|---|---|---|---|
| Parent | 15195037 | Jun 2016 | US |
| Child | 15279134 | US |
| Number | Date | Country | |
|---|---|---|---|
| Parent | 15681256 | Aug 2017 | US |
| Child | 16442268 | US | |
| Parent | 15279134 | Sep 2016 | US |
| Child | 15681256 | US |
